

Session text above this point is available in the transcript,  
available from the **Transcript Assistant** on the toolbar.

AU Remuzzi A; Perico N; Amuchastegui C S; Malanchini B; Mazerska M; Battaglia C; Bertani T; Remuzzi G  
 CS Mario Negri Institute for Pharmacological Research, Bergamo, Italy.  
 SO Journal of the American Society of Nephrology : JASN, (1993 Jul) 4 (1) 40-9.  
 Journal code: 9013836. ISSN: 1046-6673.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199310  
 ED Entered STN: 19940117  
 Last Updated on STN: 19940117  
 Entered Medline: 19931027

L9 ANSWER 632 OF 632 MEDLINE on STN

Full  Current  
 Text  References

AN 92201503 MEDLINE  
 DN PubMed ID: 1551487  
 TI Renal functional reserve in the early stage of experimental **diabetes**.  
 AU De Nicola L; Blantz R C; Gabai F B  
 CS Division of Nephrology-Hypertension, University of California, San Diego School of Medicine.  
 NC DK-28602 (NIDDK)  
 SO Diabetes, (1992 Mar) 41 (3) 267-73.  
 Journal code: 0372763. ISSN: 0012-1797.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 199204  
 ED Entered STN: 19920509  
 Last Updated on STN: 19980206  
 Entered Medline: 19920427

=> d an ti au so ab kwic 625

L9 ANSWER 625 OF 632 MEDLINE on STN

Full  Current  
 Text  References

AN 95279772 MEDLINE  
 TI Antihypertensive and renal-protective effects of **losartan** in streptozotocin **diabetic** rats.  
 AU Kohzuki M; Yasujima M; Kanazawa M; Yoshida K; Fu L P; Obara K; Saito T; Abe K  
 SO Journal of hypertension, (1995 Jan) 13 (1) 97-103.  
 Journal code: 8306882. ISSN: 0263-6352.  
 AB OBJECTIVE: To assess the renal benefits of a specific angiotensin II receptor antagonist, **losartan**, in **diabetic** rats with renal impairment. DESIGN AND METHODS: Uninephrectomized streptozotocin **diabetic** spontaneously hypertensive rats (SHR) were randomly assigned to receive vehicle, or to receive **losartan** or captopril, or both, intraperitoneally via osmotic minipumps for 8 weeks. RESULTS: Blood pressure and urinary protein excretion in the **diabetic** SHR increased progressively during the experimental period. Both captopril treatment and **losartan** treatment completely blocked the development of hypertension in **diabetic** SHR. Simultaneous administration of captopril and **losartan** did not enhance

the antihypertensive effects of **losartan** treatment or captopril treatment. Furthermore, **losartan** treatment, captopril treatment and **losartan** + captopril treatment all significantly decreased urinary protein excretion, urinary albumin excretion and serum creatinine to the same extent. These effects were sustained for the entire experimental period and were not associated with any significant changes in body weight, urine volume, urine sugar and urinary electrolytes excretion. These results were confirmed by morphological analysis of kidneys in each group of rats. **Losartan** treatment, captopril treatment and **losartan+captopril** treatment all significantly and effectively protected against an increase in the percentage of focal glomerular sclerosis. **Losartan** treatment and captopril treatment both significantly attenuated the increase in heart weight: body weight ratio. The heart weight: body weight ratio in the **losartan**-treated group was significantly lower than in the captopril-treated group. CONCLUSIONS: These results indicate that hypertension could accelerate **diabetic** renal impairment and that **losartan** has antihypertensive and renoprotective effects in this rat model. They also suggest that the antihypertensive and renoprotective effects of captopril treatment in this rat model are caused mainly by inhibition of angiotensin II production rather than stimulation of the kallikrein-kinin system or of vasodilator prostaglandins. The difference in potency between **losartan** treatment and captopril treatment to attenuate the increase in heart weight: body weight ratio might partly explain the existence in the heart of angiotensin-forming pathways, which are not dependent on angiotensin converting enzyme.

TI Antihypertensive and renal-protective effects of **losartan** in streptozotocin **diabetic** rats.

AB OBJECTIVE: To assess the renal benefits of a specific angiotensin II receptor antagonist, **losartan**, in **diabetic** rats with renal impairment.

DESIGN AND METHODS: Uninephrectomized streptozotocin **diabetic** spontaneously hypertensive rats (SHR) were randomly assigned to receive vehicle, or to receive **losartan** or captopril, or both, intraperitoneally via osmotic minipumps for 8 weeks. RESULTS: Blood pressure and urinary protein excretion in the **diabetic** SHR increased progressively during the experimental period. Both captopril treatment and **losartan** treatment completely blocked the development of hypertension in **diabetic** SHR. Simultaneous administration of captopril and **losartan** did not enhance the antihypertensive effects of **losartan** treatment or captopril treatment. Furthermore, **losartan** treatment, captopril treatment and **losartan** + captopril treatment all significantly decreased urinary protein excretion; urinary albumin excretion and serum creatinine to the same extent. These . . . urine sugar and urinary electrolytes excretion. These results were confirmed by morphological analysis of kidneys in each group of rats. **Losartan** treatment, captopril treatment and **losartan+captopril** treatment all significantly and effectively protected against an increase in the percentage of focal glomerular sclerosis. **Losartan** treatment and captopril treatment both significantly attenuated the increase in heart weight: body weight ratio. The heart weight: body weight ratio in the **losartan**-treated group was significantly lower than in the captopril-treated group. CONCLUSIONS: These results indicate that hypertension could accelerate **diabetic** renal impairment and that **losartan** has antihypertensive and renoprotective effects in this rat model. They also suggest that the antihypertensive and renoprotective effects of captopril . . . of angiotensin II production rather than stimulation of the kallikrein-kinin system or of vasodilator prostaglandins. The difference in potency between **losartan** treatment and captopril treatment to attenuate the increase in heart weight: body weight ratio might partly explain the existence in . . .

CT . . . Check Tags: Male; Support, Non-U.S. Gov't

\*Angiotensin II: AI, antagonists & inhibitors

Animals

\*Biphenyl Compounds: PD, pharmacology

Captopril: PD, pharmacology

\***Diabetes Mellitus, Experimental: DT, drug therapy**  
**Diabetes Mellitus, Experimental: ME, metabolism**  
 Drug Therapy, Combination  
 Glomerulosclerosis, Focal: ME, metabolism  
 Glomerulosclerosis, Focal: PA, pathology  
 Glomerulosclerosis, Focal: PC, prevention. . . . therapy  
 Hypertension: ME, metabolism  
 Hypertension: PA, pathology  
 \*Imidazoles: PD, pharmacology  
 Kidney: CY, cytology  
 \*Kidney: DE, drug effects  
 Kidney: ME, metabolism  
**Losartan**  
 Organ Weight  
 Random Allocation  
 Rats  
 Rats, Inbred SHR  
 \*Receptors, Angiotensin: AI, antagonists & inhibitors  
 \*Tetrazoles: PD, pharmacology  
 RN 11128-99-7 (Angiotensin II); 114798-26-4 (Losartan); 62571-86-2  
 (Captopril)

=> d an ti au so ab kwic 622

L9 ANSWER 622 OF 632 MEDLINE on STN

Full  Group  
 Text  References

AN 95360953 MEDLINE  
 TI A new class of therapeutic agents: the angiotensin II receptor antagonists.  
 AU Timmermans P B; Smith R D  
 SO Cardiologia (Rome, Italy), (1994 Dec) 39 (12 Suppl 1) 397-400.  
 Journal code: 8506637. ISSN: 0393-1978.  
 AB Angiotensin II (Ang II) is the primary mediator of the renin-angiotensin system (RAS). Inappropriate control of the RAS is critically involved in the development and maintenance of hypertension and congestive heart failure. The actions of Ang II are thought to be mediated by specific surface receptors on the various target organs. At present, two receptors for Ang II have been firmly established in mammals, including man. According to current nomenclature, **losartan** represents the prototype antagonist of the Ang II type 1 (AT1) receptor and does not possess significant affinity for the so-called AT2 receptor. **Losartan** is the first of a new class of orally active, nonpeptide Ang II receptor antagonists able to very specifically and selectively inhibit the RAS while lacking the agonistic effects of the peptide receptor antagonists, e.g. saralasin, or the bradykinin potentiating effects of the angiotensin converting enzyme (ACE) inhibitors. Virtually all of the known actions of Ang II, e.g. those defined by Ang II itself, saralasin, ACE or renin-inhibitors are blocked by **losartan**, emphasizing the major role of this distinct Ang II receptor subtype in mediating the responses of Ang II. The functional correlate of the AT2 receptor remains poorly understood. In several models of experimental and genetic hypertension, AT1 receptor antagonists are effective antihypertensive agents with similar efficacy to that of ACE and renin-inhibitors. In animal models of renal disease, AT1 receptor antagonists significantly decrease proteinuria, protect against **diabetic** glomerulopathy and increase survival in stroke-prone spontaneously hypertensive rats. (ABSTRACT TRUNCATED AT 250 WORDS)  
 AB . . . organs. At present, two receptors for Ang II have been firmly established in mammals, including man. According to current nomenclature, **losartan** represents the prototype antagonist of the Ang II type 1 (AT1) receptor and does not possess significant affinity for the so-called AT2 receptor. **Losartan** is the first of a new class of orally active,

L1        6582 S (TELMISARTAN OR IRBESARTAN OR VALSARTAN OR LOSARTAN OR CANDES  
L2        803910 S (INFLAMMATORY? OR METABOLIC OR DIABETES OR HYPERTENSION)  
L3        2917 S L1 AND L2  
L4        221923 S INFLAMMATOR?  
L5        141 S L1 AND L4  
L6        629189 S (METABOLIC OR DIABET? OR HYPERTEN?)  
L7        3072 S L1 AND L6  
L8        242415 S (DIABET?)  
L9        632 S L1 AND L8

=> s (telmisartan or irbesartan)  
   252 TELMISARTAN  
   593 IRBESARTAN  
L10      799 (TELMISARTAN OR IRBESARTAN)

=> s l8 and l10  
L11      171 L8 AND L10

=> d 1-171

L11 ANSWER 1 OF 171      MEDLINE on STN

Full     Plain  
 Text     References

AN 2005019574      IN-PROCESS  
DN PubMed ID: 15645839  
TI [Irbesartan in the treatment of arterial hypertension].  
   Irbesartan v lecbe arterialni hypertenze.  
AU Widimsky J Jr; Zizka J; Haas T  
CS III. interni klinika 1. LF UK, Praha.  
SO Vnitri lekarstvi, (2000 Jun) 46 (6) 337-40.  
   Journal code: 0413602. ISSN: 0042-773X.  
CY Czech Republic  
DT Journal; Article; (JOURNAL ARTICLE)  
LA Czech  
FS IN-PROCESS; NONINDEXED; Priority Journals  
ED Entered STN: 20050114  
   Last Updated on STN: 20050114

L11 ANSWER 2 OF 171      MEDLINE on STN

Full     Plain  
 Text     References

AN 2004642306      IN-PROCESS  
DN PubMed ID: 15617852  
TI Telmisartan is a promising cardiometabolic sartan due to its unique  
   PPAR-gamma-inducing property.  
AU Yamagishi S; Takeuchi M  
CS Department of Medicine, Kurume University School of Medicine, Kurume,  
   Japan.  
SO Medical hypotheses, (2005) 64 (3) 476-8.  
   Journal code: 7505668. ISSN: 0306-9877.  
CY Scotland: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals  
ED Entered STN: 20041228  
   Last Updated on STN: 20041228

L11 ANSWER 3 OF 171      MEDLINE on STN

Full     Plain  
 Text     References

AN 2004638171      IN-PROCESS  
DN PubMed ID: 15613069  
TI Irbesartan is projected to be cost and life saving in a Spanish setting  
   for treatment of patients with type 2 diabetes, hypertension, and

microalbuminuria.  
AU Palmer Andrew J; Annemans Lieven; Roze Stephane; Lapuerta Pablo; Chen Roland; Gabriel Sylvie; Carita Paulo; Rodby Roger A; de Zeeuw Dick; Parving Hans-Henrik; De Alvaro Fernando  
CS CORE-Center for Outcomes Research, Binningen/Basel, Switzerland.  
SO Kidney international. Supplement, (2005 Jan) (93) S52-4.  
Journal code: 7508622. ISSN: 0098-6577.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals  
ED Entered STN: 20041223  
Last Updated on STN: 20041223

L11 ANSWER 4 OF 171 MEDLINE on STN

Full  Citata  References  
 Text

AN 2004638166 IN-PROCESS  
DN PubMed ID: 15613064  
TI Microalbuminuria in hypertensive patients: Evaluation of one-year treatment with **irbesartan**.  
AU de Alvaro Fernando; Velasco Olga; Honorato Jesus; Calvo Carlos; Parrondo Inma  
CS Hospital Universitario La Paz, Madrid, Spain. (on Behalf of KORAL HT Investigators).  
SO Kidney international. Supplement, (2005 Jan) (93) S29-34.  
Journal code: 7508622. ISSN: 0098-6577.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals  
ED Entered STN: 20041223  
Last Updated on STN: 20041223

L11 ANSWER 5 OF 171 MEDLINE on STN

Full  Citata  References  
 Text

AN 2004637797 IN-PROCESS  
DN PubMed ID: 15614015  
TI Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system.  
AU Kurtz Theodore W; Pravenec Michal  
CS Department of Laboratory Medicine, University of California, San Francisco, California 94107, USA.. [KurtzT@Labmed2.ucsf.edu](mailto:KurtzT@Labmed2.ucsf.edu)  
NC HL63709 (NHLBI)  
TW01236 (FIC)  
SO Journal of hypertension, (2004 Dec) 22 (12) 2253-61.  
Journal code: 8306882. ISSN: 0263-6352.  
CY England: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS IN-PROCESS; NONINDEXED; Priority Journals  
ED Entered STN: 20041223  
Last Updated on STN: 20041224

L11 ANSWER 6 OF 171 MEDLINE on STN

Full  Citata  References  
 Text

AN 2004616421 IN-PROCESS  
DN PubMed ID: 15592575  
TI Clinical and Experimental Aspects of Olmesartan Medoxomil, a New Angiotensin II Receptor Antagonist.  
AU Yoshida Kazunori; Kohzuki Masahiro  
CS Department of Medicine, Furukawa City Hospital, Furukawa, Miyagi 989-6183, Japan.. [kazunori@gakushikai.jp](mailto:kazunori@gakushikai.jp)

SO Cardiovascular drug reviews, (2004 Winter) 22 (4) 285-308.  
 Journal code: 9006912. ISSN: 0897-5957.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals  
 ED Entered STN: 20041220  
 Last Updated on STN: 20041220

L11 ANSWER 7 OF 171 MEDLINE on STN

Full  Cited by  
 Text  References

AN 2004607860 IN-PROCESS  
 DN PubMed ID: 15353911  
 TI Effect of **irbesartan** on the antioxidant defence system and nitric oxide release in **diabetic** rat kidney.  
 AU Anjaneyulu Muragundla; Chopra Kanwaljit  
 CS Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.  
 SO American journal of nephrology, (2004 Sep-Oct) 24 (5) 488-96.  
 Journal code: 8109361. ISSN: 0250-8095.  
 CY Switzerland  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS IN-PROCESS; NONINDEXED; Priority Journals  
 ED Entered STN: 20041208  
 Last Updated on STN: 20041220

L11 ANSWER 8 OF 171 MEDLINE on STN

Full  Cited by  
 Text  References

AN 2004574889 IN-PROCESS  
 DN PubMed ID: 15316606  
 TI Effect of **irbesartan** on nitrotyrosine generation in non-hypertensive **diabetic** patients.  
 AU Ceriello A; Assaloni R; Da Ros R; Maier A; Quagliaro L; Piconi L; Esposito K; Giugliano D  
 CS Department of Experimental and Clinical Pathology and Medicine, University of Udine, P. le S. Maria della Misericordia, 33100 Udine, Italy.. [ceriello@uniud.it](mailto:ceriello@uniud.it)  
 SO Diabetologia, (2004 Sep) 47 (9) 1535-40.  
 Journal code: 0006777. ISSN: 0012-186X.  
 CY Germany: Germany, Federal Republic of  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS IN-PROCESS; NONINDEXED; Priority Journals  
 ED Entered STN: 20041120  
 Last Updated on STN: 20041220

L11 ANSWER 9 OF 171 MEDLINE on STN

Full  Cited by  
 Text  References

AN 2004560107 IN-PROCESS  
 DN PubMed ID: 15526250  
 TI How different urinary albumin excretion rates can predict progression to nephropathy and the effect of treatment in hypertensive **diabetics**.  
 AU Llewelyn D E Huw; Garcia-Puig Juan  
 CS Department of Medicine, Luton and Dunstable Hospital, Luton, Bedfordshire LU1 4OZ, UK.. [HuwLlewelyn@I&d-anglo-nhs.org.uk](mailto:HuwLlewelyn@I&d-anglo-nhs.org.uk)  
 SO Journal of the renin-angiotensin-aldosterone system : JRAAS, (2004 Sep) 5 (3) 141-5.  
 Journal code: 100971636. ISSN: 1470-3203.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English

FS IN-PROCESS; NONINDEXED; Priority Journals  
 ED Entered STN: 20041110  
 Last Updated on STN: 20041220

L11 ANSWER 10 OF 171 MEDLINE on STN

	Full	Cited by
	Text	References

AN 2004553661 MEDLINE  
 DN PubMed ID: 15516696  
 TI Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 **diabetes** and nephropathy.  
 CM Comment in: N Engl J Med. 2004 Nov 4;351(19):1934-6. PubMed ID: 15516698  
 AU Barnett Anthony H; Bain Stephen C; Bouter Paul; Karlberg Bengt; Madsbad Sten; Jervell Jak; Mustonen Jukka  
 CS Division of Medical Sciences, University of Birmingham and Birmingham Heartlands and Solihull National Health Service Trust (Teaching), Birmingham, United Kingdom. (Diabetics Exposed to Telmisartan and Enalapril Study Group). [anthony.barnett@heartsol.wmids.nhs.uk](mailto:anthony.barnett@heartsol.wmids.nhs.uk)  
 SO New England journal of medicine, (2004 Nov 4) 351 (19) 1952-61.  
 Journal code: 0255562. ISSN: 1533-4406.  
 CY United States  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (MULTICENTER STUDY)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 200411  
 ED Entered STN: 20041105  
 Last Updated on STN: 20041113  
 Entered Medline: 20041112

L11 ANSWER 11 OF 171 MEDLINE on STN

	Full	Cited by
	Text	References

AN 2004550348 IN-PROCESS  
 DN PubMed ID: 15523550  
 TI Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency.  
 AU Weinbergova Otilie; Metelka Rudolf; Vymetal Jiri; Konecny Karel; Kosatikova Zdena  
 CS Faculty of Medicine, Palacky University, Olomouc, Czech Republic.  
 SO Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, (2004 Jul) 148 (1) 69-73.  
 Journal code: 101140142. ISSN: 1213-8118.  
 CY Czech Republic  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals  
 ED Entered STN: 20041104  
 Last Updated on STN: 20041220

L11 ANSWER 12 OF 171 MEDLINE on STN

	Full	Cited by
	Text	References

AN 2004544934 IN-PROCESS  
 DN PubMed ID: 15516153  
 TI Prevention of type 2 **diabetes** mellitus through inhibition of the Renin-Angiotensin system.  
 AU Scheen Andre J  
 CS Division of Diabetes, Department of Medicine, Nutrition and Metabolic Disorders, CHU Sart Tilman, Liege, Belgium.. [Andre.Scheen@chu.ulg.ac.be](mailto:Andre.Scheen@chu.ulg.ac.be)  
 SO Drugs, (2004) 64 (22) 2537-65.  
 Journal code: 7600076. ISSN: 0012-6667.  
 CY New Zealand

DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS IN-PROCESS; NONINDEXED; Priority Journals  
 ED Entered STN: 20041102  
 Last Updated on STN: 20041220

L11 ANSWER 13 OF 171 MEDLINE on STN

Full  Claim  
 Text  References

AN 2004530677 MEDLINE  
 DN PubMed ID: 15500387  
 TI **Telmisartan** - killing two birds with one stone.  
 AU Doggrell Sheila A  
 CS School of Biomedical Sciences, University of Queensland, QLD 4072,  
 Australia.. [s\\_doggrell@yahoo.com](mailto:s_doggrell@yahoo.com)  
 SO Expert opinion on pharmacotherapy, (2004 Nov) 5 (11) 2397-400. Ref: 12  
 Journal code: 100897346. ISSN: 1744-7666.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 LA English  
 FS Priority Journals  
 EM 200412  
 ED Entered STN: 20041026  
 Last Updated on STN: 20041220  
 Entered Medline: 20041210

L11 ANSWER 14 OF 171 MEDLINE on STN

Full  Claim  
 Text  References

AN 2004530667 MEDLINE  
 DN PubMed ID: 15500377  
 TI **Telmisartan**/hydrochlorothiazide combination therapy in the treatment of  
 essential hypertension.  
 AU Schmieder Roland E  
 CS University Erlangen-Nuremberg, Department of Medicine IV, Germany..  
[roland.schmieder@rzmail.uni-erlangen.de](mailto:roland.schmieder@rzmail.uni-erlangen.de)  
 SO Expert opinion on pharmacotherapy, (2004 Nov) 5 (11) 2303-10. Ref: 36  
 Journal code: 100897346. ISSN: 1744-7666.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 LA English  
 FS Priority Journals  
 EM 200412  
 ED Entered STN: 20041026  
 Last Updated on STN: 20041220  
 Entered Medline: 20041210

L11 ANSWER 15 OF 171 MEDLINE on STN

Full  Claim  
 Text  References

AN 2004520077 MEDLINE  
 DN PubMed ID: 15490772  
 TI [IRMA-pRacs: **irbesartan** in the treatment of microalbuminuria and  
 proteinuria in patients with type 2 **diabetes** and hypertension-  
 prospective observational study involving 38,016 patients in the general  
 practice setting].  
 IRMA-pRACS: **Irbesartan** zur Behandlung der Mikroalbuminurie und  
 Proteinurie bei Patienten mit Typ 2 **Diabetes** und Hypertonie.  
 AU Lehnert H; Bramlage P; Pittrow D; Kirch W  
 CS Klinik fur Endokrinologie und Stoffwechselkrankheiten der Universitat  
 Magdeburg.. [Hendrik.Lehnert@medizin.uni-magdeburg.de](mailto:Hendrik.Lehnert@medizin.uni-magdeburg.de)  
 SO MMW Fortschritte der Medizin, (2003 Oct 9) 145 Suppl 3 81-7.

CY Journal code: 100893959. ISSN: 1438-3276.  
 CY Germany: Germany, Federal Republic of  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (MULTICENTER STUDY)  
 LA German  
 FS Priority Journals  
 EM 200412  
 ED Entered STN: 20041020  
 Last Updated on STN: 20041223  
 Entered Medline: 20041222

L11 ANSWER 16 OF 171 MEDLINE on STN

Full  Cited  References  
 Text

AN 2004516495 IN-PROCESS  
 DN PubMed ID: 15485429  
 TI Impact of **irbesartan**, blood pressure control, and proteinuria on renal outcomes in the **Irbesartan Diabetic Nephropathy Trial**.  
 AU Hunsicker Lawrence G; Atkins Robert C; Lewis Julia B; Braden Gregory; de Crespigny Paul J Champion; DeFerrari Giacomo; Drury Paul; Locatelli Francesco; Wiegmann Thomas B; Lewis Edmund J  
 CS Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, Iowa, USA. (Collaborative Study Group). [lawrence-hunsicker@uiowa.edu](mailto:lawrence-hunsicker@uiowa.edu)  
 SO Kidney international. Supplement, (2004 Nov) (92) S99-101.  
 Journal code: 7508622. ISSN: 0098-6577.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS IN-PROCESS; NONINDEXED; Priority Journals  
 ED Entered STN: 20041019  
 Last Updated on STN: 20041219

L11 ANSWER 17 OF 171 MEDLINE on STN

Full  Cited  References  
 Text

AN 2004516485 IN-PROCESS  
 DN PubMed ID: 15485418  
 TI Predictors of cardiovascular events in patients with type 2 **diabetic** nephropathy and hypertension: a case for albuminuria.  
 AU Anavekar Nagesh S; Gans Daniel J; Berl Tomas; Rohde Richard D; Cooper William; Bhaumik Amitabha; Hunsicker Lawrence G; Rouleau Jean-Lucien; Lewis Julia B; Rosendorff Clive; Porush Jerome G; Drury Paul L; Esmatjes Enric; Raz Itamar; Vanhille Phillippe; Locatelli Francesco; Goldhaber Samuel; Lewis Edmund J; Pfeffer Marc A  
 CS Brigham & Women's Hospital, Boston, Massachusetts 02115, USA.  
 SO Kidney international. Supplement, (2004 Nov) (92) S50-5.  
 Journal code: 7508622. ISSN: 0098-6577.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS IN-PROCESS; NONINDEXED; Priority Journals  
 ED Entered STN: 20041019  
 Last Updated on STN: 20041219

L11 ANSWER 18 OF 171 MEDLINE on STN

Full  Cited  References  
 Text

AN 2004516471 IN-PROCESS  
 DN PubMed ID: 15485404  
 TI Health economics studies assessing **irbesartan** use in patients with hypertension, type 2 **diabetes**, and microalbuminuria.  
 AU Palmer Andrew J; Rodby Roger A  
 CS Center for Outcomes Research, Binningen/Basel, Switzerland..

ap@thecenter.ch  
 SO Kidney international. Supplement, (2004 Nov) (92) S118-20.

Journal code: 7508622. ISSN: 0098-6577.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS IN-PROCESS; NONINDEXED; Priority Journals

ED Entered STN: 20041019

Last Updated on STN: 20041219

L11 ANSWER 19 OF 171 MEDLINE on STN

Full  Cited by  
 Text  References

AN 2004507537 MEDLINE

DN PubMed ID: 15476904

TI Comparison of the effects of **telmisartan** and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 **diabetes mellitus** and mild hypertension: a 12-month, randomized, double-blind study.

AU Derosa Giuseppe; Cicero Arrigo F G; Bertone Gianandrea; Piccinni Mario N; Fogari Elena; Ciccarelli Leonardina; Fogari Roberto

CS Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.. [giuderosa@tin.it](mailto:giuderosa@tin.it)

SO Clinical therapeutics, (2004 Aug) 26 (8) 1228-36.  
 Journal code: 7706726. ISSN: 0149-2918.

CY United States

DT (CLINICAL TRIAL)

Journal; Article; (JOURNAL ARTICLE)  
 (RANDOMIZED CONTROLLED TRIAL)

LA English

FS Priority Journals

EM 200410

ED Entered STN: 20041013

Last Updated on STN: 20041030

Entered Medline: 20041029

L11 ANSWER 20 OF 171 MEDLINE on STN

Full  Cited by  
 Text  References

AN 2004501447 IN-PROCESS

DN PubMed ID: 15470286

TI Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies.

AU Ram C Ventika S

CS Texas Blood Pressure Institute, Dallas Nephrology Associates, University of Texas Southwestern Medical Center, Dallas, TX, USA.. [ramv@dneph.com](mailto:ramv@dneph.com)

SO Journal of clinical hypertension (Greenwich, Conn.), (2004 Oct) 6 (10) 569-77.  
 Journal code: 100888554. ISSN: 1524-6175.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS IN-PROCESS; NONINDEXED; Priority Journals

ED Entered STN: 20041008

Last Updated on STN: 20041219

L11 ANSWER 21 OF 171 MEDLINE on STN

Full  Cited by  
 Text  References

AN 2004495787 IN-PROCESS

DN PubMed ID: 15462695

TI The effect of **irbesartan** in reducing cardiovascular risk in hypertensive type 2 **diabetic** patients: an observational study in 16,600 patients in primary care.

AU Bramlage P; Pittrow D; Kirch W

CS Institute of Clinical Pharmacology, Medical Faculty Carl Gustav Carus, Technical University, Dresden, Germany.. [peter.bramlage@mailbox.tu-dresden.de](mailto:peter.bramlage@mailbox.tu-dresden.de)  
 SO Current medical research and opinion, (2004 Oct) 20 (10) 1625-31.  
 Journal code: 0351014. ISSN: 0300-7995.  
 CY England: United Kingdom.  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS IN-PROCESS; NONINDEXED; Priority Journals  
 ED Entered STN: 20041007  
 Last Updated on STN: 20041219

L11 ANSWER 22 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 2004474802 IN-PROCESS  
 DN PubMed ID: 15116142  
 TI An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.  
 AU Palmer A J; Annemans L; Roze S; Lamotte M; Rodby R A; Bilous R W  
 CS Center for Outcomes Research, Basel, Switzerland.. [ap@thecenter.ch](mailto:ap@thecenter.ch)  
 SO Journal of human hypertension, (2004 Oct) 18 (10) 733-8.  
 Journal code: 8811625. ISSN: 0950-9240.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS IN-PROCESS; NONINDEXED; Priority Journals  
 ED Entered STN: 20040924  
 Last Updated on STN: 20041219

L11 ANSWER 23 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 2004474796 IN-PROCESS  
 DN PubMed ID: 15071488  
 TI Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus.  
 AU Mugellini A; Preti P; Zoppi A; Corradi L; Fogari E; Derosa G; Fogari R  
 CS Department of Internal Medicine and Therapeutics, Clinica Medica II, IRCCS Policlinico S Matteo, University of Pavia, Pavia, Italy.  
 SO Journal of human hypertension, (2004 Oct) 18 (10) 687-91.  
 Journal code: 8811625. ISSN: 0950-9240.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS IN-PROCESS; NONINDEXED; Priority Journals  
 ED Entered STN: 20040924  
 Last Updated on STN: 20041219

L11 ANSWER 24 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 2004474051 MEDLINE  
 DN PubMed ID: 15384790  
 TI Effects of angiotensin II receptor blocker (irbesartan) on peritoneal membrane functions.  
 AU Coronel Francisco; Berni Ana; Cigarran Secundino; Calvo Natividad; Herrero Jose A  
 CS Nephrology Department, Peritoneal Dialysis Unit, Hospital Clinico San Carlos, Madrid, Spain.. [fcoronel.hcsc@salud.madrid.org](mailto:fcoronel.hcsc@salud.madrid.org)  
 SO Advances in peritoneal dialysis. Conference on Peritoneal Dialysis, (2004) 20 27-30.  
 Journal code: 9104803. ISSN: 1197-8554.  
 CY Canada

DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200411  
 ED Entered STN: 20040924  
 Last Updated on STN: 20041106  
 Entered Medline: 20041106

L11 ANSWER 25 OF 171 MEDLINE on STN

Full  Cited by  
 Text  References

AN 2004463882 MEDLINE  
 DN PubMed ID: 15353571  
 TI The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus.  
 CM Comment in: Ann Pharmacother. 2004 Dec;38(12):2176; author reply 2176-7.  
 PubMed ID: 15599959  
 AU Coyle James D; Gardner Stephanie F; White C Michael  
 CS Division of Pharmacy Practice and Administration, College of Pharmacy, the Ohio State University, Columbus, OH, USA.  
 SO Annals of pharmacotherapy, (2004 Oct) 38 (10) 1731-8. Ref: 31  
 Journal code: 9203131. ISSN: 1060-0280.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200412  
 ED Entered STN: 20040921  
 Last Updated on STN: 20041223  
 Entered Medline: 20041222

L11 ANSWER 26 OF 171 MEDLINE on STN

Full  Cited by  
 Text  References

AN 2004463479 MEDLINE  
 DN PubMed ID: 15373137  
 TI [A threat to cardiovascular risk patients. "Activated renin-angiotensin system promotes end organ damage" (interview by Waldtraud Paukstadt)].  
 Bedroht kardiovaskulare Risikopatienten. "Aktiviertes Renin-Angiotensin-System fordert Endorganschaden".  
 AU Schunkert Heribert  
 SO MMW Fortschritte der Medizin, (2004 Jun 3) 146 (23) 60.  
 Journal code: 100893959. ISSN: 1438-3276.  
 CY Germany: Germany, Federal Republic of  
 DT (INTERVIEW)  
 LA German  
 FS Priority Journals  
 EM 200412  
 ED Entered STN: 20040921  
 Last Updated on STN: 20041222  
 Entered Medline: 20041221

L11 ANSWER 27 OF 171 MEDLINE on STN

Full  Cited by  
 Text  References

AN 2004461742 MEDLINE  
 DN PubMed ID: 15369420  
 TI Emerging trends for prevention and treatment of **diabetic** nephropathy: blockade of the RAAS and BP control.  
 AU Hunsicker Lawrence G  
 CS University of Iowa Medical School, Iowa City, USA.. lawrence-hunsicker@uiowa.edu  
 SO J Manag Care Pharm, (2004 Sep) 10 (5 Suppl A) S12-7. Ref: 12

Journal code: 9605854. ISSN: 1083-4087.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200412  
 ED Entered STN: 20040917  
 Last Updated on STN: 20041221  
 Entered Medline: 20041220

L11 ANSWER 28 OF 171 MEDLINE on STN

<input type="checkbox"/> Full	<input checked="" type="checkbox"/> Cited
<input type="checkbox"/> Text	<input type="checkbox"/> References

AN 2004461741 MEDLINE  
 DN PubMed ID: 15369419  
 TI Pharmacoeconomic challenges in the management of **diabetic** nephropathy.  
 AU Rodby Roger A  
 CS Rush University Medical Center, 1426 W. Washington Blvd., Chicago, IL  
 60607, USA.. [rrodby@mindspring.com](mailto:rrodby@mindspring.com)  
 SO J Manag Care Pharm, (2004 Sep) 10 (5 Suppl A) S6-11.  
 Journal code: 9605854. ISSN: 1083-4087.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200412  
 ED Entered STN: 20040917  
 Last Updated on STN: 20041221  
 Entered Medline: 20041220

L11 ANSWER 29 OF 171 MEDLINE on STN

<input type="checkbox"/> Full	<input checked="" type="checkbox"/> Cited
<input type="checkbox"/> Text	<input type="checkbox"/> References

AN 2004398533 IN-PROCESS  
 DN PubMed ID: 15302981  
 TI Effects of **telmisartan** compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 **diabetic** patients: a randomized, double-blind, placebo-controlled 12-month study.  
 AU Derosa Giuseppe; Ragonesi Pietro D; Mugellini Amedeo; Ciccarelli Leonardina; Fogari Roberto  
 CS Department of Internal Medicine and Therapeutics, University of Pavia, Italy.. [giuderosa@tin.it](mailto:giuderosa@tin.it)  
 SO Hypertension research : official journal of the Japanese Society of Hypertension, (2004 Jul) 27 (7) 457-64.  
 Journal code: 9307690. ISSN: 0916-9636.  
 CY Japan  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS IN-PROCESS; NONINDEXED; Priority Journals  
 ED Entered STN: 20040811  
 Last Updated on STN: 20041219

L11 ANSWER 30 OF 171 MEDLINE on STN

<input type="checkbox"/> Full	<input checked="" type="checkbox"/> Cited
<input type="checkbox"/> Text	<input type="checkbox"/> References

AN 2004380116 MEDLINE  
 DN PubMed ID: 15283313  
 TI [Cost-effectiveness of Ibersartan in type II **diabetic** nephropathy with hypertension. A Spanish perspective].  
 Coste-efectividad de **irbesartan** en pacientes hipertensos con nefropatía **diabética** tipo II: una perspectiva española.

AU Palmer A J; Annemans L; Roze S; Lamotte M; Rodby R A; de Alvaro F  
 CS Hospital La Paz, Servicio de Nefrologia, Madrid. (Grupo de Estudio Colaborativo IDNT).  
 SO Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, (2004) 24 (3) 231-8.  
 Journal code: 8301215. ISSN: 0211-6995.  
 CY Spain  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA Spanish  
 FS Priority Journals  
 EM 200410  
 ED Entered STN: 20040801  
 Last Updated on STN: 20041008  
 Entered Medline: 20041007

L11 ANSWER 31 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2004372884 IN-PROCESS  
 DN PubMed ID: 15277414  
 TI Cost-effectiveness of early **irbesartan** treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late **irbesartan** treatment in patients with type 2 **diabetes**, hypertension, and renal disease.  
 AU Palmer Andrew J; Annemans Lieven; Roze Stephane; Lamotte Mark; Lapuerta Pablo; Chen Roland; Gabriel Sylvie; Carita Paulo; Rodby Roger A; de Zeeuw Dick; Parving Hans-Henrik  
 CS CORE-Center for Outcomes Research, Buendtenmattstrasse 40, 4102 Binningen/Basel, Switzerland.. [ap@thecenter.ch](mailto:ap@thecenter.ch)  
 SO Diabetes care, (2004 Aug) 27 (8) 1897-903.  
 Journal code: 7805975. ISSN: 0149-5992.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS IN-PROCESS; NONINDEXED; Priority Journals  
 ED Entered STN: 20040728  
 Last Updated on STN: 20041219

L11 ANSWER 32 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2004371856 MEDLINE  
 DN PubMed ID: 15276098  
 TI Clinically unrecognized Q-wave myocardial infarction in patients with **diabetes mellitus**, systemic hypertension, and nephropathy.  
 AU Aguilar David; Goldhaber Samuel Z; Gans Daniel J; Levey Andrew S; Porush Jerome G; Lewis Julia B; Rouleau Jean-Lucien; Berl Tomas; Lewis Edmund J; Pfeffer Marc A  
 CS Division of Cardiology, University of Texas Health Science Center, Houston, 77030, USA. (Collaborative Study Group). [david.aguilar@uth.tmc.edu](mailto:david.aguilar@uth.tmc.edu)  
 SO American journal of cardiology, (2004 Aug 1) 94 (3) 337-9.  
 Journal code: 0207277. ISSN: 0002-9149.  
 CY United States  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 200408  
 ED Entered STN: 20040728  
 Last Updated on STN: 20040827  
 Entered Medline: 20040826

L11 ANSWER 33 OF 171 MEDLINE on STN

Full	Gated
Text	References

AN 2004336962 MEDLINE  
 DN PubMed ID: 15213879  
 TI [Health economic aspects of the use of **irbesartan** in patients in Germany with type 2 **diabetes**, nephropathy and hypertension].  
 Gesundheitsökonomische Aspekte der Anwendung von **Irbesartan** bei Patienten mit Typ-2-**Diabetes**, Nephropathie und Hypertonie in Deutschland.  
 CM Comment on: Dtsch Med Wochenschr. 2004 Jan 2;129(1-2):13-8. PubMed ID: 14703575  
 AU Schute L L  
 SO Deutsche medizinische Wochenschrift, (2004 Jun 18) 129 (25-26) 1448; author reply 1448.  
 Journal code: 0006723. ISSN: 0012-0472.  
 CY Germany: Germany, Federal Republic of  
 DT Commentary  
 Letter  
 LA German  
 FS Priority Journals  
 EM 200407  
 ED Entered STN: 20040709  
 Last Updated on STN: 20040723  
 Entered Medline: 20040722

L11 ANSWER 34 OF 171 MEDLINE on STN

Full	Gated
Text	References

AN 2004313076 MEDLINE  
 DN PubMed ID: 15215792  
 TI Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating **telmisartan**, ramipril, and their combination in high-risk patients: the Ongoing **Telmisartan** Alone and in Combination with Ramipril Global Endpoint Trial/**Telmisartan** Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.  
 AU Teo Koon; Yusuf Salim; Sleight Peter; Anderson Craig; Mookadam Farouk; Ramos Barbara; Hilbrich Lutz; Pogue Janice; Schumacher Helmut  
 CS McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5. (ONTARGET/TRANSCEND Investigators). [teok@mcmaster.ca](mailto:teok@mcmaster.ca)  
 SO American heart journal, (2004 Jul) 148 (1) 52-61.  
 Journal code: 0370465. ISSN: 1097-6744.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 200410  
 ED Entered STN: 20040625  
 Last Updated on STN: 20041006  
 Entered Medline: 20041005

L11 ANSWER 35 OF 171 MEDLINE on STN

Full	Gated
Text	References

AN 2004262874 MEDLINE  
 DN PubMed ID: 15161820  
 TI Kidney function during and after withdrawal of long-term **irbesartan** treatment in patients with type 2 **diabetes** and microalbuminuria: response to Andersen, Brochner-Mortensen, and Parving.  
 CM Comment on: Diabetes Care. 2003 Dec;26(12):3296-302. PubMed ID: 14633817  
 AU Kaiser Thomas; Florack Christiane; Sawicki Peter T  
 SO Diabetes care, (2004 Jun) 27 (6) 1521; author reply 1521-2.  
 Journal code: 7805975. ISSN: 0149-5992.

CY United States  
 DT Commentary  
 Letter  
 LA English  
 FS Priority Journals  
 EM 200501  
 ED Entered STN: 20040527  
 Last Updated on STN: 20050112  
 Entered Medline: 20050111

L11 ANSWER 36 OF 171 MEDLINE on STN

Full  Clang  
 Text  References

AN 2004256998 MEDLINE  
 DN PubMed ID: 15155118  
 TI Challenges in improving prognosis and therapy: the Ongoing **Telmisartan** Alone and in Combination with Ramipril Global End point Trial programme.  
 AU Zimmermann Mathias; Unger Thomas  
 CS Center for Cardiovascular Research/Institute for Pharmacology and Toxicology, Charite-University Medicine Berlin, Germany.  
 SO Expert opinion on pharmacotherapy, (2004 May) 5 (5) 1201-8.  
 Journal code: 100897346. ISSN: 1465-6566.  
 CY England: United Kingdom  
 DT (CLINICAL TRIAL)  
 (CONTROLLED CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200410  
 ED Entered STN: 20040525  
 Last Updated on STN: 20041015  
 Entered Medline: 20041014

L11 ANSWER 37 OF 171 MEDLINE on STN

Full  Clang  
 Text  References

AN 2004245201 MEDLINE  
 DN PubMed ID: 15101793  
 TI **Irbesartan**: a review of its use in hypertension and in the management of diabetic nephropathy.  
 AU Croom Katherine F; Curran Monique P; Goa Karen L; Perry Caroline M  
 CS Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand.. [demail@adis.co.nz](mailto:demail@adis.co.nz)  
 SO Drugs, (2004) 64 (9) 999-1028. Ref: 148  
 Journal code: 7600076. ISSN: 0012-6667.  
 CY New Zealand  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200407  
 ED Entered STN: 20040518  
 Last Updated on STN: 20040728  
 Entered Medline: 20040726

L11 ANSWER 38 OF 171 MEDLINE on STN

Full  Clang  
 Text  References

AN 2004229921 MEDLINE  
 DN PubMed ID: 15007034  
 TI Identification of **telmisartan** as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.  
 AU Benson Stephen C; Pershad Singh Harrihar A; Ho Christopher I; Chittiboyina Amar; Desai Prashant; Pravenec Michal; Qi Nianning; Wang Jiaming; Avery

CS Mitchell A; Kurtz Theodore W  
 Department of Biological Sciences, California State University, Hayward,  
 USA.  
 NC 2R42AR44767-02A2 (NIAMS)  
 HL63709 (NHLBI)  
 TW01236 (FIC)  
 SO Hypertension, (2004 May) 43 (5) 993-1002.  
 Journal code: 7906255. ISSN: 1524-4563.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200410  
 ED Entered STN: 20040510  
 Last Updated on STN: 20041009  
 Entered Medline: 20041008

L11 ANSWER 39 OF 171 MEDLINE on STN

Full	Clang
Text	References

AN 2004224638 MEDLINE  
 DN PubMed ID: 15117841  
 TI Angiotensin type 1 receptor blockers induce peroxisome  
 proliferator-activated receptor-gamma activity.  
 AU Schupp Michael; Janke Jurgen; Clasen Ronald; Unger Thomas; Kintscher  
 Ulrich  
 CS Center for Cardiovascular Research, Institut fur Pharmakologie und  
 Toxikologie, Campus Charite-Mitte, Charite-Universitätsmedizin Berlin,  
 Berlin, Germany.  
 SO Circulation, (2004 May 4) 109 (17) 2054-7.  
 Journal code: 0147763. ISSN: 1524-4539.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 200409  
 ED Entered STN: 20040505  
 Last Updated on STN: 20040911  
 Entered Medline: 20040910

L11 ANSWER 40 OF 171 MEDLINE on STN

Full	Clang
Text	References

AN 2004218897 MEDLINE  
 DN PubMed ID: 15117095  
 TI What is the impact of PRIME on real-life **diabetic** nephropathy?.  
 AU Ruilope L M  
 CS Chief Hypertension Unit, Hospital 12 de Octubre, Madrid 28041, Spain.  
 SO International journal of clinical practice, (2004 Mar) 58 (3) 268-76.  
 Ref: 43  
 Journal code: 9712381. ISSN: 1368-5031.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200407  
 ED Entered STN: 20040501  
 Last Updated on STN: 20040707  
 Entered Medline: 20040706

L11 ANSWER 41 OF 171 MEDLINE on STN

Full	Clang
Text	References

AN 2004212671 MEDLINE  
 DN PubMed ID: 15109447  
 TI Effect of **irbesartan** on angiotensin II-induced hypertrophy of human proximal tubular cells.  
 AU Liu Bi-Cheng; Sun Jing; Chen Qi; Luo Dong-Dong; Ma Kun-Ling; Ruan Xiong-Zhong  
 CS Institute of Nephrology, Zhongda Hospital, Southeast University School of Medicine, Nanjing 210009, China.. [kidney@jlonline.com](mailto:kidney@jlonline.com)  
 SO Chinese medical journal, (2004 Apr) 117 (4) 547-51.  
 Journal code: 7513795. ISSN: 0366-6999.  
 CY China  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200407  
 ED Entered STN: 20040428  
 Last Updated on STN: 20040709  
 Entered Medline: 20040708

L11 ANSWER 42 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 2004208380 MEDLINE  
 DN PubMed ID: 15047614  
 TI Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat.  
 AU Tikellis Christos; Wookey Peter J; Candido Riccardo; Andrikopoulos Sof; Thomas Merlin C; Cooper Mark E  
 CS Danielle Alberti Memorial Centre for Diabetic Complications, Baker Medical Research Institute, Melbourne, Victoria, Australia.  
 SO Diabetes, (2004 Apr) 53 (4) 989-97.  
 Journal code: 0372763. ISSN: 0012-1797.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 200405  
 ED Entered STN: 20040427  
 Last Updated on STN: 20040521  
 Entered Medline: 20040520

L11 ANSWER 43 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 2004168950 MEDLINE  
 DN PubMed ID: 15061687  
 TI Safety of **telmisartan** in patients with arterial hypertension : an open-label observational study.  
 AU Michel Martin C; Bohner Herbert; Koster Jurgen; Schafers Rafael; Heemann Uwe  
 CS Department of Pharmacology and Pharmacotherapy, University of Amsterdam, Amsterdam, The Netherlands.. [m.c.michel@amc.uva.nl](mailto:m.c.michel@amc.uva.nl)  
 SO Drug safety : an international journal of medical toxicology and drug experience, (2004) 27 (5) 335-44.  
 Journal code: 9002928. ISSN: 0114-5916.  
 CY New Zealand  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200408  
 ED Entered STN: 20040406  
 Last Updated on STN: 20040813  
 Entered Medline: 20040812

L11 ANSWER 44 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2004164707 MEDLINE  
DN PubMed ID: 15030294  
TI AT1-receptor antagonism in hypertension: what has been learned with **irbesartan**?.  
AU Waeber Bernard; Burnier Michel  
CS University Hospital, Division of Pathophysiology, Lausanne, Switzerland..  
**bwaeber@chuv.hospvd.ch**  
SO Expert Rev Cardiovasc Ther, (2003 May) 1 (1) 23-33. Ref: 71  
Journal code: 101182328. ISSN: 1477-9072.  
CY England: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)  
LA English  
FS Priority Journals  
EM 200405  
ED Entered STN: 20040403  
Last Updated on STN: 20040510  
Entered Medline: 20040507

L11 ANSWER 45 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2004157142 MEDLINE  
DN PubMed ID: 15023892  
TI **Irbesartan** but not amlodipine suppresses **diabetes**-associated atherosclerosis.  
AU Candido Riccardo; Allen Terri J; Lassila Markus; Cao Zemin; Thallas Vicki;  
Cooper Mark E; Jandeleit-Dahm Karin A  
CS Vascular Division, Baker Heart Research Institute, PO Box 6492, Melbourne  
8008, Victoria, Australia.  
SO Circulation, (2004 Mar 30) 109 (12) 1536-42.  
Journal code: 0147763. ISSN: 1524-4539.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 200407  
ED Entered STN: 20040331  
Last Updated on STN: 20040716  
Entered Medline: 20040715

L11 ANSWER 46 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2004136098 MEDLINE  
DN PubMed ID: 15029149  
TI [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].  
Kandesartan - novyi blokator AT(1)-angiotenzinovykh retseptorov:  
osobennosti farmakologii i opyt ispol'zovaniia pri arterial'noi  
gipertenzii.  
AU Sidorenko B A; Preobrazhenskii D V; Soplevenko A V; Ivanova N A; Stetsenko  
T M  
CS Presidential Medical Center of Russia; ul. Marshala Timoschenko 15, 121356  
Moscow, Russia.  
SO Kardiologiya, (2004) 44 (1) 55-65. Ref: 76  
Journal code: 0376351. ISSN: 0022-9040.  
CY Russia: Russian Federation  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, ACADEMIC)

LA Russian  
 FS Priority Journals  
 EM 200408  
 ED Entered STN: 20040319  
 Last Updated on STN: 20040806  
 Entered Medline: 20040805

## L11 ANSWER 47 OF 171 MEDLINE on STN

Full     Clang  
 Text     References

AN 2004126091 MEDLINE  
 DN PubMed ID: 15017527  
 TI Angiotensin receptor blockers in **diabetic** nephropathy: renal and cardiovascular end points.  
 AU Parving Hans-Henrik; Andersen Steen; Jacobsen Peter; Christensen Per K;  
 Rossing Kasper; Hovind Peter; Rossing Peter; Tarnow Lise  
 CS Steno Diabetes Center, Copenhagen, Denmark.. [hparving@dadlnet.dk](mailto:hparving@dadlnet.dk)  
 SO Seminars in nephrology, (2004 Mar) 24 (2) 147-57. Ref: 70  
 Journal code: 8110298. ISSN: 0270-9295.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200412  
 ED Entered STN: 20040319  
 Last Updated on STN: 20041219  
 Entered Medline: 20041206

## L11 ANSWER 48 OF 171 MEDLINE on STN

Full     Clang  
 Text     References

AN 2004111431 MEDLINE  
 DN PubMed ID: 15000928  
 TI Clinical inquiries. Are ARBs or ACE inhibitors preferred for nephropathy in **diabetes**?  
 AU Foreman Brett H; Chambliss M Lee  
 CS Moses Cone Health System, Greensboro, NC, USA.  
 SO Journal of family practice, (2004 Mar) 53 (3) 241-2. Ref: 6  
 Journal code: 7502590. ISSN: 0094-3509.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 200404  
 ED Entered STN: 20040306  
 Last Updated on STN: 20040501  
 Entered Medline: 20040430

## L11 ANSWER 49 OF 171 MEDLINE on STN

Full     Clang  
 Text     References

AN 2004085581 MEDLINE  
 DN PubMed ID: 14974331  
 TI [Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].  
 Gefasspatient mit hohem Infarktrisiko. Schutzt der AT1-Blocker so gut wie ein ACE-Hemmer?  
 AU Anonymous  
 SO MMW Fortschritte der Medizin, (2003 Dec 18) 145 (51-52) 39.  
 Journal code: 100893959. ISSN: 1438-3276.  
 CY Germany: Germany, Federal Republic of

DT Journal; Article; (JOURNAL ARTICLE)  
 LA German  
 FS Priority Journals  
 EM 200404  
 ED Entered STN: 20040221  
 Last Updated on STN: 20040428  
 Entered Medline: 20040427

L11 ANSWER 50 OF 171 MEDLINE on STN

Full  Citations  
 Text  References

AN 2004077919 MEDLINE  
 DN PubMed ID: 14968145  
 TI Economic evaluation of the use of **irbesartan** and amlodipine in the treatment of **diabetic** nephropathy in patients with hypertension in Canada.  
 AU Coyle Douglas; Rodby Roger A  
 CS Ottawa Health Research Institute, Ottawa Hospital, Ottawa, Ontario, Canada.. [dcoyle@ohri.ca](mailto:dcoyle@ohri.ca)  
 SO Canadian journal of cardiology, (2004 Jan) 20 (1) 71-9.  
 Journal code: 8510280. ISSN: 0828-282X.  
 CY Canada  
 DT (EVALUATION STUDIES)  
 Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200403  
 ED Entered STN: 20040218  
 Last Updated on STN: 20040304  
 Entered Medline: 20040303

L11 ANSWER 51 OF 171 MEDLINE on STN

Full  Citations  
 Text  References

AN 2004048276 MEDLINE  
 DN PubMed ID: 14749145  
 TI Losartan and other angiotensin II antagonists for nephropathy in type 2 **diabetes** mellitus: a review of the clinical trial evidence.  
 AU Ruilope Luis M; Segura Julian  
 CS Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain.. [luis.m.ruilope@teleline.es](mailto:luis.m.ruilope@teleline.es)  
 SO Clinical therapeutics, (2003 Dec) 25 (12) 3044-64. Ref: 86  
 Journal code: 7706726. ISSN: 0149-2918.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200403  
 ED Entered STN: 20040130  
 Last Updated on STN: 20040319  
 Entered Medline: 20040318

L11 ANSWER 52 OF 171 MEDLINE on STN

Full  Citations  
 Text  References

AN 2004026407 MEDLINE  
 DN PubMed ID: 14725209  
 TI [New possibilities in clinical use of angiotensin II receptor inhibitors]. Az angiotenzin II-receptor-gatlok klinikai alkalmazasanak uj lehetosegei.  
 AU Matos Lajos  
 CS Fovarosi Szent Janos Korhaz, Kardiologial Jarobeteg-rendeles.  
 SO Orvosi hetilap, (2003 Dec 7) 144 (49) 2419-23. Ref: 23  
 Journal code: 0376412. ISSN: 0030-6002.

CY Hungary  
 DT Journal; Article; (JOURNAL ARTICLE)  
   General Review; (REVIEW)  
   (REVIEW, TUTORIAL)  
 LA Hungarian  
 FS Priority Journals  
 EM 200403  
 ED Entered STN: 20040117  
   Last Updated on STN: 20040317  
   Entered Medline: 20040316

L11 ANSWER 53 OF 171 MEDLINE on STN

Full  
 Cited  
 Text  
 References

AN 2004012072 MEDLINE  
 DN PubMed ID: 14709365  
 TI Clinical and nutritional correlates of C-reactive protein in type 2 diabetic nephropathy.  
 AU Friedman Alton N; Hunsicker Lawrence G; Selhub Jacob; Boston Andrew G  
 CS Division of Nephrology, Indiana University School of Medicine, 1481 W. 10th St.-111N, Indianapolis, IN 46202, USA.. [allfried@iupui.edu](mailto:allfried@iupui.edu)  
 NC R01 HL 67695-02 (NHLBI)  
 SO Atherosclerosis, (2004 Jan) 172 (1) 121-5.  
   Journal code: 0242543. ISSN: 0021-9150.  
 CY Ireland  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200405  
 ED Entered STN: 20040108  
   Last Updated on STN: 20040521  
   Entered Medline: 20040520

L11 ANSWER 54 OF 171 MEDLINE on STN

Full  
 Cited  
 Text  
 References

AN 2004006384 MEDLINE  
 DN PubMed ID: 14703575  
 TI [Health economic consequences of the use of **irbesartan** in patients in Germany with type 2 **diabetes**, nephropathy and hypertension]. Gesundheitsökonomische Aspekte der Anwendung von **Irbesartan** bei Patienten mit Typ-2-**Diabetes**, Nephropathie und Hypertonie in Deutschland.  
 CM Comment in: Dtsch Med Wochenschr. 2004 Jun 18;129(25-26):1448; author reply 1448. PubMed ID: 15213879  
 AU Palmer A J; Annemans L; Roze S; Lamotte M; Rodby R A; Ritz E  
 CS Center for Outcomes Research, Basel, Schweiz.. [AP@thecenter.ch](mailto:AP@thecenter.ch)  
 SO Deutsche medizinische Wochenschrift, (2004 Jan 2) 129 (1-2) 13-8.  
   Journal code: 0006723. ISSN: 0012-0472.  
 CY Germany: Germany, Federal Republic of  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA German  
 FS Priority Journals  
 EM 200402  
 ED Entered STN: 20040106  
   Last Updated on STN: 20040218  
   Entered Medline: 20040217

L11 ANSWER 55 OF 171 MEDLINE on STN

Full  
 Cited  
 Text  
 References

AN 2003611423 MEDLINE  
 DN PubMed ID: 14694914  
 TI The **telmisartan** Programme of Research to show **Telmisartan** End-organ protection (PROTECTION) programme.

AU Weber Michael  
 CS State University of New York Downstate College of Medicine, New York,  
 USA.. [michaelwebermd@cs.com](mailto:michaelwebermd@cs.com)  
 SO Journal of hypertension, (2003 Jul) 21 Suppl 6 S37-46. Ref: 63  
 Journal code: 8306882. ISSN: 0263-6352.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200405  
 ED Entered STN: 20031226  
 Last Updated on STN: 20040526  
 Entered Medline: 20040525

L11 ANSWER 56 OF 171 MEDLINE on STN

Full	Clang
Text	References

AN 2003574421 MEDLINE  
 DN PubMed ID: 14655481  
 TI [Prospective treatment study of **irbesartan**. **Diabetic** kidneys regain function].  
 Prospektive Versorgungsstudie zu **Irbesartan**. **Diabetikernieren** erholen sich wieder.  
 AU Lehnert H; Bramlage P; Pittrow D; Kirch W  
 CS Klinik fur Endokrinologie und Stoffwechselkrankheiten, Medizinische Fakultat, Otto-von-Guericke-Universitat, Leipziger Strasse 44, D-39120 Magdeburg.. [Hendrik.Lehnert@medizin.uni-magdeburg.de](mailto:Hendrik.Lehnert@medizin.uni-magdeburg.de)  
 SO MMW Fortschritte der Medizin, (2003 Oct 9) 145 (41) 41.  
 Journal code: 100893959. ISSN: 1438-3276.  
 CY Germany: Germany, Federal Republic of  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA German  
 FS Priority Journals  
 EM 200403  
 ED Entered STN: 20031216  
 Last Updated on STN: 20040318  
 Entered Medline: 20040317

L11 ANSWER 57 OF 171 MEDLINE on STN

Full	Clang
Text	References

AN 2003553881 MEDLINE  
 DN PubMed ID: 14633817  
 TI Kidney function during and after withdrawal of long-term **irbesartan** treatment in patients with type 2 **diabetes** and microalbuminuria.  
 CM Comment in: Diabetes Care. 2004 Jun;27(6):1521; author reply 1521-2.  
 PubMed ID: 15161820  
 AU Andersen Steen; Brochner-Mortensen Jens; Parving Hans-Henrik  
 CS Steno Diabetes Center, Gentofte, Denmark. (Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group). [stan@dadlnet.dk](mailto:stan@dadlnet.dk)  
 SO Diabetes care, (2003 Dec) 26 (12) 3296-302.  
 Journal code: 7805975. ISSN: 0149-5992.  
 CY United States  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (MULTICENTER STUDY)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LA English  
 FS Priority Journals  
 EM 200407  
 ED Entered STN: 20031125  
 Last Updated on STN: 20040714  
 Entered Medline: 20040713

L11 ANSWER 58 OF 171 MEDLINE on STN

Full	Claro
Text	References

AN 2003545686 MEDLINE  
 DN PubMed ID: 14625161  
 TI Recommendations for the management of special populations: renal disease in **diabetes**.  
 AU Raij Leopoldo  
 CS Nephrology-Hypertension Division, University of Miami School of Medicine, Nephrology-Hypertension Section, Veterans Affairs Medical Center, Miami, Florida 33125, USA.. [LRaij@med.miami.edu](mailto:LRaij@med.miami.edu)  
 SO American journal of hypertension : journal of the American Society of Hypertension, (2003 Nov) 16 (11 Pt 2) 46S-49S. Ref: 16  
 Journal code: 8803676. ISSN: 0895-7061.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200403  
 ED Entered STN: 20031120  
 Last Updated on STN: 20040325  
 Entered Medline: 20040324

L11 ANSWER 59 OF 171 MEDLINE on STN

Full	Claro
Text	References

AN 2003508524 MEDLINE  
 DN PubMed ID: 14586737  
 TI Treatment of **diabetic** nephropathy with angiotensin II receptor antagonist.  
 AU Lewis Edmund J; Lewis Julia B  
 CS Rush/Presbyterian/St. Luke's Medical Center, 1426 W. Washington Blvd., Chicago, IL 60607, USA.. [hfolmer@rush.edu](mailto:hfolmer@rush.edu)  
 SO Clinical and experimental nephrology, (2003 Mar) 7 (1) 1-8. Ref: 20  
 Journal code: 9709923. ISSN: 1342-1751.  
 CY Japan  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200311  
 ED Entered STN: 20031031  
 Last Updated on STN: 20031219  
 Entered Medline: 20031126

L11 ANSWER 60 OF 171 MEDLINE on STN

Full	Claro
Text	References

AN 2003495602 MEDLINE  
 DN PubMed ID: 14573338  
 TI Role of systolic blood pressureon the progression of kidney damage in an experimental model of type 2 **diabetes** mellitus, obesity, and hypertension (Zucker rats).  
 AU Gonzalez-Albarran Olga; Gomez Oscar; Ruiz Esther; Vieitez Paula; Garcia-Robles Rafael  
 CS Department of Endocrinology, Hospital Ramon y Cajal, Madrid, Spain.  
 SO American journal of hypertension : journal of the American Society of Hypertension, (2003 Nov) 16 (11 Pt 1) 979-85.  
 Journal code: 8803676. ISSN: 0895-7061.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)

LA English  
 FS Priority Journals  
 EM 200402  
 ED Entered STN: 20031024  
 Last Updated on STN: 20040302  
 Entered Medline: 20040226

## L11 ANSWER 61 OF 171 MEDLINE on STN

Full  Cited  References  
 Text

AN 2003456790 MEDLINE  
 DN PubMed ID: 14518593  
 TI Angiotensin II stimulates platelet-derived growth factor-B gene expression in cultured retinal pericytes through intracellular reactive oxygen species generation.  
 AU Amano S; Yamagishi S; Inagaki Y; Okamoto T  
 CS Department of Medicine, Kurume University School of Medicine, Kurume, Japan.  
 SO International journal of tissue reactions, (2003) 25 (2) 51-5.  
 CY Journal code: 8302116. ISSN: 0250-0868.  
 CY Switzerland  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200404  
 ED Entered STN: 20031002  
 Last Updated on STN: 20040501  
 Entered Medline: 20040430

## L11 ANSWER 62 OF 171 MEDLINE on STN

Full  Cited  References  
 Text

AN 2003453123 MEDLINE  
 DN PubMed ID: 14513950  
 TI The telmisartan programme of research to show Telmisartan End-organ protection (PROTECTION) programme.  
 AU Weber Michael  
 CS State University of New York Downstate College of Medicine, New York, USA.. michaelwebermd@cs.com  
 SO Journal of hypertension. Supplement : official journal of the International Society of Hypertension, (2003 Jul) 21 Suppl 6 S37-46. Ref: 63  
 CY Journal code: 8501422. ISSN: 0952-1178.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200404  
 ED Entered STN: 20030930  
 Last Updated on STN: 20040429  
 Entered Medline: 20040428

## L11 ANSWER 63 OF 171 MEDLINE on STN

Full  Cited  References  
 Text

AN 2003445129 MEDLINE  
 DN PubMed ID: 12943484  
 TI Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes.  
 CM Erratum in: Expert Opin Pharmacother. 2003 Oct;4(10):1887  
 AU Postma Maarten J; Kruidhof Hanneke; de Jong-van den Berg Lolkje T W; de Zeeuw Dick  
 CS Groningen University Institute for Drug Exploration/University of

Groningen Research Institute of Pharmacy (GUIDE/GRIP), Department of Social Pharmacy, Pharmaco-epidemiology & Pharmacotherapy, The Netherlands.. [m.postma@farm.rug.nl](mailto:m.postma@farm.rug.nl)

SO Expert opinion on pharmacotherapy, (2003 Sep) 4 (9) 1543-50. Ref: 48  
Journal code: 100897346. ISSN: 1465-6566.

CY England: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)

LA English

FS Priority Journals

EM 200310

ED Entered STN: 20030925  
Last Updated on STN: 20031015  
Entered Medline: 20031014

L11 ANSWER 64 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2003438759 MEDLINE

DN PubMed ID: 13679481

TI An economic evaluation of **irbesartan** in the treatment of patients with type 2 **diabetes**, hypertension and nephropathy: cost-effectiveness of **Irbesartan in Diabetic Nephropathy Trial (IDNT)** in the Belgian and French settings.

AU Palmer Andrew J; Annemans Lieven; Roze Stephane; Lamotte Mark; Rodby Roger A; Cordonnier Daniel J

CS Center for Outcomes Research, St Johanns-Ring 139, CH-4056 Basel, Switzerland.. [ap@thecenter.ch](mailto:ap@thecenter.ch)

SO Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, (2003 Oct) 18 (10) 2059-66.  
Journal code: 8706402. ISSN: 0931-0509.

CY England: United Kingdom

DT (EVALUATION STUDIES)  
Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200402

ED Entered STN: 20030923  
Last Updated on STN: 20040207  
Entered Medline: 20040206

L11 ANSWER 65 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2003413122 MEDLINE

DN PubMed ID: 12951837

TI Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation.

AU Yamagishi S; Amano S; Inagaki Y; Okamoto T; Inoue H; Takeuchi M; Choei H; Sasaki N; Kikuchi S

CS Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.. [shoichi@med.kurume-u.ac.jp](mailto:shoichi@med.kurume-u.ac.jp)

SO Drugs under experimental and clinical research, (2003) 29 (2) 75-80.  
Journal code: 7802135. ISSN: 0378-6501.

CY Switzerland

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200405

ED Entered STN: 20030904  
Last Updated on STN: 20040511

Entered Medline: 20040510

L11 ANSWER 66 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 2003407853 MEDLINE  
 DN PubMed ID: 12946554  
 TI The cost-effectiveness of **irbesartan** in the treatment of hypertensive patients with type 2 **diabetic** nephropathy.  
 AU Rodby Roger A; Chiou Chion Fang; Borenstein Jeff; Smitten Allison; Sengupta Nishan; Palmer Andrew J; Roze Stephane; Annemans Lieven; Simon Teresa A; Chen Roland S; Lewis Edmund J  
 CS Rush-Presbyterian St. Luke's Medical Center, Chicago, Illinois, USA.  
 (Collaborative Study Group). [rrodby@mindspring.com](mailto:rrodby@mindspring.com)  
 SO Clinical therapeutics, (2003 Jul) 25 (7) 2102-19.  
 Journal code: 7706726. ISSN: 0149-2918.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200311  
 ED Entered STN: 20030830  
 Last Updated on STN: 20031218  
 Entered Medline: 20031125

L11 ANSWER 67 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 2003376046 MEDLINE  
 DN PubMed ID: 12891278  
 TI [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and **diabetic** nephropathy].  
 Blokator AT1-angiotenzinovyykh retseptorov lozartan. Chast' II. Opyt ispol'zovaniia dlia lecheniia gipertoniceskoi bolezni i **diabeticheskoi** nefropatii.  
 AU Sidorenko B A; Preobrazhenskii D V; Stetsenko T M; Tarykina E V; Tsurko V V  
 SO Kardiologiya, (2003) 43 (2) 88-95. Ref: 50  
 Journal code: 0376351. ISSN: 0022-9040.  
 CY Russia: Russian Federation  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA Russian  
 FS Priority Journals  
 EM 200310  
 ED Entered STN: 20030813  
 Last Updated on STN: 20031028  
 Entered Medline: 20031027

L11 ANSWER 68 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 2003366374 MEDLINE  
 DN PubMed ID: 12899808  
 TI Do **irbesartan** and amlodipine reduce cardiovascular events in **diabetic** patients?.  
 CM Comment on: Ann Intern Med. 2003 Apr 1;138(7):542-9. PubMed ID: 12667024  
 AU Millard Peter S  
 CS Family Practice Residency Program, Eastern Maine Medical Center, Bangor, USA.. [pmillard@emh.org](mailto:pmillard@emh.org)  
 SO Journal of family practice, (2003 Aug) 52 (8) 593-4.  
 Journal code: 7502590. ISSN: 0094-3509.  
 CY United States  
 DT Commentary

Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS PUBMED-NOT-MEDLINE  
 EM 200308  
 ED Entered STN: 20030806  
 Last Updated on STN: 20030830  
 Entered Medline: 20030829

L11 ANSWER 69 OF 171 MEDLINE on STN

Full  Cited  References  
 Text

AN 2003351910 MEDLINE  
 DN PubMed ID: 12882713  
 TI Influence of **irbesartan** on renal hypertrophy and thickening of glomerular basement-membrane in streptozotocin-induced **diabetic** rats.  
 AU Liu Bi-cheng; Luo Dong-dong; Sun Jing; Ma Kun-ling; Ruan Xiong-zhong  
 CS Renal Division, Zhong Da Hospital, Southeast University School of Medicine, Nanjing 210009, China.  
 SO Zhonghua nei ke za zhi [Chinese journal of internal medicine], (2003 May) 42 (5) 320-3.  
 Journal code: 16210490R. ISSN: 0578-1426.  
 CY China  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA Chinese  
 FS Priority Journals  
 EM 200411  
 ED Entered STN: 20030729  
 Last Updated on STN: 20031218  
 Entered Medline: 20041119

L11 ANSWER 70 OF 171 MEDLINE on STN

Full  Cited  References  
 Text

AN 2003345777 MEDLINE  
 DN PubMed ID: 12877087  
 TI Antihypertensive therapy in renal dysfunction.  
 AU Ito Sadayoshi  
 CS Division of Nephrology, Endocrinology, and Vascular Medicine, Department of Medicine, Tohoku University School of Medicine.  
 SO Nippon rinsho. Japanese journal of clinical medicine, (2003 Jul) 61 (7) 1210-8. Ref: 16  
 Journal code: 0420546. ISSN: 0047-1852.  
 CY Japan  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA Japanese  
 FS Priority Journals  
 EM 200309  
 ED Entered STN: 20030725  
 Last Updated on STN: 20030926  
 Entered Medline: 20030925

L11 ANSWER 71 OF 171 MEDLINE on STN

Full  Cited  References  
 Text

AN 2003315557 MEDLINE  
 DN PubMed ID: 12844467  
 TI Lessons from trials in hypertensive type 2 **diabetic** patients.  
 AU Ruilope Luis M  
 CS Unidad de Hipertension, Hospital 12 de Octubre, 28041 Madrid, Spain..  
luis.m.ruilope@teleline.es  
 SO Current hypertension reports, (2003 Aug) 5 (4) 322-8. Ref: 58  
 Journal code: 100888982. ISSN: 1522-6417.  
 CY United States

DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200311  
 ED Entered STN: 20030708  
 Last Updated on STN: 20031218  
 Entered Medline: 20031121

L11 ANSWER 72 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2003310074 MEDLINE  
 DN PubMed ID: 12838494  
 TI Outcome studies in **diabetic** nephropathy.  
 AU Mohanram Anupama; Toto Robert D  
 CS University of Texas Southwestern Medical Center Dallas, Dallas, TX  
 75390-8856, USA.  
 SO Seminars in nephrology, (2003 May) 23 (3) 255-71. Ref: 191  
 Journal code: 8110298. ISSN: 0270-9295.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, ACADEMIC)  
 LA English  
 FS Priority Journals  
 EM 200310  
 ED Entered STN: 20030703  
 Last Updated on STN: 20031101  
 Entered Medline: 20031031

L11 ANSWER 73 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2003291323 MEDLINE  
 DN PubMed ID: 12818479  
 TI Effect of **telmisartan** on the proteinuria and circadian blood pressure profile in chronic renal patients.  
 AU Cupisti Adamasco; Rizza Giovanni Manca; D'Alessandro Claudia; Morelli Ester; Barsotti Giuliano  
 CS Nephrology Unit, Department of Internal Medicine, University of Pisa, Via Roma 67, 56100, Pisa, Italy.. [cupisti@med.unipi.it](mailto:cupisti@med.unipi.it)  
 SO Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, (2003 May-Jun) 57 (3-4) 169-72.  
 Journal code: 8213295. ISSN: 0753-3322.  
 CY France  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200402  
 ED Entered STN: 20030624  
 Last Updated on STN: 20040211  
 Entered Medline: 20040210

L11 ANSWER 74 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2003282079 MEDLINE  
 DN PubMed ID: 12808810  
 TI [Dangerous deficits in management of hypertensive **diabetic** patients. A kidney check is far from standard procedure].  
 Gefahrliche Mangel bei der Versorgung von hypertensiven **Diabetikern**.  
 Nieren-Check noch lange nicht Standard.  
 AU Anonymous

SO MMW Fortschritte der Medizin, (2003 Apr 24) 145 (17) 55.  
 Journal code: 100893959. ISSN: 1438-3276.  
 CY Germany: Germany, Federal Republic of  
 DT News Announcement  
 LA German  
 FS Priority Journals  
 EM 200310  
 ED Entered STN: 20030618  
 Last Updated on STN: 20031028  
 Entered Medline: 20031027

L11 ANSWER 75 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2003255815 MEDLINE  
 DN PubMed ID: 12781906  
 TI The ongoing **telmisartan** alone and in combination with ramipril global endpoint trial program.  
 AU Unger Thomas  
 CS Institute of Pharmacology and Toxicology, Charite Hospital, Humboldt University at Berlin, Berlin, Germany.. [Thomas.unger@charite.de](mailto:Thomas.unger@charite.de)  
 SO American journal of cardiology, (2003 May 22) 91 (10A) 28G-34G. Ref: 52  
 Journal code: 0207277. ISSN: 0002-9149.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 200307  
 ED Entered STN: 20030604  
 Last Updated on STN: 20030710  
 Entered Medline: 20030709

L11 ANSWER 76 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2003255813 MEDLINE  
 DN PubMed ID: 12781904  
 TI Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine.  
 CM Comment in: Am J Cardiol. 2003 Oct 1;92(7):900. PubMed ID: 14516906  
 AU Ball Stephen G; White William B  
 CS Department of Cardiovascular Medicine, University of Leeds, Leeds, United Kingdom.  
 SO American journal of cardiology, (2003 May 22) 91 (10A) 15G-21G. Ref: 30  
 Journal code: 0207277. ISSN: 0002-9149.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 200307  
 ED Entered STN: 20030604  
 Last Updated on STN: 20030710  
 Entered Medline: 20030709

L11 ANSWER 77 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2003197207 MEDLINE  
 DN PubMed ID: 12716839  
 TI The true overall mortality of unselected nephropathic type 2 **diabetic** patients with mild to moderate renal insufficiency.

AU Biesenbach Georg; Janko Otmar  
 SO Diabetes care, (2003 May) 26 (5) 1639-40.  
 Journal code: 7805975. ISSN: 0149-5992.  
 CY United States  
 DT Letter  
 LA English  
 FS Priority Journals  
 EM 200312  
 ED Entered STN: 20030429  
 Last Updated on STN: 20031219  
 Entered Medline: 20031218

L11 ANSWER 78 OF 171 MEDLINE on STN

Full  Cited  References  
 Text

AN 2003162989 MEDLINE  
 DN PubMed ID: 12667050  
 TI Summaries for patients. Effects of blood pressure drugs in patients with **diabetes** and kidney disease.  
 CM Original report in: Ann Intern Med. 2003 Apr 1;138(7):542-9. PubMed ID: 12667024  
 AU Anonymous  
 SO Annals of internal medicine, (2003 Apr 1) 138 (7) I43.  
 Journal code: 0372351. ISSN: 1539-3704.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (PATIENT EDUCATION HANDOUT)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 200304  
 ED Entered STN: 20030409  
 Last Updated on STN: 20030418  
 Entered Medline: 20030417

L11 ANSWER 79 OF 171 MEDLINE on STN

Full  Cited  References  
 Text

AN 2003162985 MEDLINE  
 DN PubMed ID: 12667024  
 TI Cardiovascular outcomes in the **Irbesartan Diabetic Nephropathy Trial** of patients with type 2 **diabetes** and overt nephropathy.  
 CM Comment in: J Fam Pract. 2003 Aug;52(8):593-4. PubMed ID: 12899808  
 Summary for patients in: Ann Intern Med. 2003 Apr 1;138(7):I43. PubMed ID: 12667050  
 AU Berl Tomas; Hunsicker Lawrence G; Lewis Julia B; Pfeffer Marc A; Porush Jerome G; Rouleau Jean-Lucien; Drury Paul L; Esmatjes Enric; Hricik Donald; Parikh Chirag R; Raz Itamar; Vanhille Philippe; Wiegmann Thomas B; Wolfe Bernard M; Locatelli Francesco; Goldhaber Samuel Z; Lewis Edmund J  
 CS University of Colorado Medical School, Denver, Colorado, USA. (Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group).  
 SO Annals of internal medicine, (2003 Apr 1) 138 (7) 542-9.  
 Journal code: 0372351. ISSN: 1539-3704.  
 CY United States  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 200304  
 ED Entered STN: 20030409  
 Last Updated on STN: 20030418  
 Entered Medline: 20030417

L11 ANSWER 80 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2003160091 MEDLINE  
DN PubMed ID: 12675866  
TI Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in **diabetic** nephropathy.  
CM Comment in: Kidney Int. 2003 Nov;64(5):1921; author reply 1921-2. PubMed ID: 14531832  
AU Jacobsen Peter; Andersen Steen; Rossing Kasper; Jensen Berit R; Parving Hans-Henrik  
CS Steno Diabetes Center, Gentofte, Denmark.. [pkjacobsen@dadlnet.dk](mailto:pkjacobsen@dadlnet.dk)  
SO Kidney international, (2003 May) 63 (5) 1874-80.  
Journal code: 0323470. ISSN: 0085-2538.  
CY United States  
DT (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
(RANDOMIZED CONTROLLED TRIAL)  
LA English  
FS Priority Journals  
EM 200312  
ED Entered STN: 20030406  
Last Updated on STN: 20031218  
Entered Medline: 20031217

L11 ANSWER 81 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2003129526 MEDLINE  
DN PubMed ID: 12643209  
TI Angiotensin receptor blockers in **diabetic** nephropathy.  
AU Price D A; Hollenberg N K  
CS Department of Medicine, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, MA 02115, USA.. [DAPrice@Partners.org](mailto:DAPrice@Partners.org)  
NC 1 R01 DK54668-01 (NIDDK)  
1P50ML 53000-01  
M01RR026376 (NCRR)  
P01AC00059916  
T32 HL-07609 (NHLBI)  
SO Current diabetes reports, (2001 Dec) 1 (3) 267-74. Ref: 64  
Journal code: 101093791. ISSN: 1534-4827.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW LITERATURE)  
LA English  
FS Priority Journals  
EM 200304  
ED Entered STN: 20030320  
Last Updated on STN: 20030406  
Entered Medline: 20030404

L11 ANSWER 82 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2003097109 MEDLINE  
DN PubMed ID: 12610003  
TI Comparative effects of **Irbesartan** on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the **Irbesartan** in Patients with Type 2 **Diabetes** and Microalbuminuria study.  
AU Rossing Kasper; Christensen Per K; Andersen Steen; Hovind Peter; Hansen Henrik Post; Parving Hans-Henrik  
CS Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark.  
(Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study).  
[krossing@dadlnet.dk](mailto:krossing@dadlnet.dk)  
SO Diabetes care, (2003 Mar) 26 (3) 569-74.

CY Journal code: 7805975. ISSN: 0149-5992.  
 CY United States  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LA English  
 FS Priority Journals  
 EM 200309  
 ED Entered STN: 20030302  
 Last Updated on STN: 20030912  
 Entered Medline: 20030911

L11 ANSWER 83 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 2003053556 MEDLINE  
 DN PubMed ID: 12563568  
 TI Effects of **telmisartan** on arterial stiffness in Type 2 **diabetes**  
 patients with essential hypertension.  
 AU Asmar Roland; Gosse Phillippe; Topouchian Jirar; N'tela Gilbert; Dudley  
 Amanda; Shepherd Gillian L  
 CS The Cardiovascular Institute, Paris, France.. [ra@icv.org](mailto:ra@icv.org)  
 SO Journal of the renin-angiotensin-aldosterone system : JRAAS, (2002 Sep) 3  
 (3) 176-80.  
 Journal code: 100971636. ISSN: 1470-3203.  
 CY England: United Kingdom  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LA English  
 FS Priority Journals  
 EM 200302  
 ED Entered STN: 20030204  
 Last Updated on STN: 20030222  
 Entered Medline: 20030221

L11 ANSWER 84 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 2003043742 MEDLINE  
 DN PubMed ID: 12553490  
 TI Angiotensin receptor antagonists in patients with nephropathy due to type  
 2 **diabetes**.  
 AU Eberhard Ritz; Dikow Ralf  
 CS Department of Internal Medicine, Ruperto Carola University, Heidelberg,  
 Germany.. [Prof.E.Ritz@t-online.de](mailto:Prof.E.Ritz@t-online.de)  
 SO Annals of medicine, (2002) 34 (7-8) 507-13. Ref: 34  
 Journal code: 8906388. ISSN: 0785-3890.  
 CY Sweden  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200304  
 ED Entered STN: 20030130  
 Last Updated on STN: 20030429  
 Entered Medline: 20030428

L11 ANSWER 85 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 2003011262 MEDLINE  
 DN PubMed ID: 12518183  
 TI Emerging role of angiotensin II type 1 receptor blockers for the treatment

of endothelial dysfunction and vascular inflammation.  
AU Mancini G B John  
CS Vancouver Hospital and Health Sciences Centre, University of British Columbia, Canada.. [mancini@interchange.ubc.ca](mailto:mancini@interchange.ubc.ca)  
SO Canadian journal of cardiology, (2002 Dec) 18 (12) 1309-16. Ref: 38  
Journal code: 8510280. ISSN: 0828-282X.  
CY Canada  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW LITERATURE)  
LA English  
FS Priority Journals  
EM 200301  
ED Entered STN: 20030109  
Last Updated on STN: 20030128  
Entered Medline: 20030127

L11 ANSWER 86 OF 171 MEDLINE on STN

Full  China  
 Text  References

AN 2003005538 MEDLINE  
DN PubMed ID: 12511232  
TI Mechanisms of **irbesartan** in prevention of renal lesion in streptozotocin-induced **diabetic** rats.  
AU Liu Bi-Cheng; Chen Qi; Luo Dong-Dong; Sun Jing; Phillips A O; Ruan Xiong-Zhong; Liu Nai-Feng  
CS Department of Pathophysiology, Nanjing Medical University, Nanjing 210002, China.. [kidney@jlonline.com](mailto:kidney@jlonline.com)  
SO Acta pharmacologica Sinica, (2003 Jan) 24 (1) 67-73.  
Journal code: 100956087. ISSN: 1671-4083.  
CY China  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 200310  
ED Entered STN: 20030105  
Last Updated on STN: 20031002  
Entered Medline: 20031001

L11 ANSWER 87 OF 171 MEDLINE on STN

Full  China  
 Text  References

AN 2002741085 MEDLINE  
DN PubMed ID: 12503943  
TI Olmesartan medoxomil: the seventh angiotensin receptor antagonist.  
AU Gardner Stephanie F; Franks Amy M  
CS Department of Pharmacy Practice, University of Arkansas for Medical Sciences, Little Rock, AR 72205-7199, USA.. [gardnerstephanie@uams.edu](mailto:gardnerstephanie@uams.edu)  
SO Annals of pharmacotherapy, (2003 Jan) 37 (1) 99-105. Ref: 29  
Journal code: 9203131. ISSN: 1060-0280.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)  
LA English  
FS Priority Journals  
EM 200304  
ED Entered STN: 20021231  
Last Updated on STN: 20030425  
Entered Medline: 20030424

L11 ANSWER 88 OF 171 MEDLINE on STN

Full  China  
 Text  References

AN 2002738413 MEDLINE

DN PubMed ID: 12501871  
 TI Pharmacologic management of **diabetic** nephropathy.  
 AU Vivian Eva M; Rubinstein Gail Breen  
 CS University of the Sciences in Philadelphia, Philadelphia College of Pharmacy, Department of Pharmacy Practice and Pharmacy Administration, Philadelphia, Pennsylvania 19104-4495, USA.. [e.vivian@usip.edu](mailto:e.vivian@usip.edu)  
 SO Clinical therapeutics, (2002 Nov) 24 (11) 1741-56; discussion 1719. Ref: 57  
 Journal code: 7706726. ISSN: 0149-2918.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200303  
 ED Entered STN: 20021228  
 Last Updated on STN: 20030401  
 Entered Medline: 20030331

L11 ANSWER 89 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2002730963 MEDLINE  
 DN PubMed ID: 12494060  
 TI [Clinical hypertensiology: analysis of trials completed in 2001-2002].  
 Klinicheskaya giperotenziologiya: analiz zavershennykh issledovanii  
 2001-2002 gg.  
 AU Karpov Iu A  
 SO Kardiologiya, (2002) 42 (10) 62-6. Ref: 16  
 Journal code: 0376351. ISSN: 0022-9040.  
 CY Russia: Russian Federation  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA Russian  
 FS Priority Journals  
 EM 200311  
 ED Entered STN: 20021221  
 Last Updated on STN: 20031104  
 Entered Medline: 20031103

L11 ANSWER 90 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2002705701 MEDLINE  
 DN PubMed ID: 12467154  
 TI [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].  
 Action des inhibiteurs de l'enzyme de conversion sur l'évolution de l'insuffisance rénale chronique.  
 AU Bernadet-Monrozies Pauline; Rostaing Lionel; Kamar Nassim; Durand Dominique  
 CS Service de néphrologie, hypertension artérielle, dialyse et transplantation, Hôpital Rangueil, 31403 Toulouse.  
 SO Presse médicale (Paris, France : 1983), (2002 Nov 9) 31 (36) 1714-20.  
 Ref: 49  
 Journal code: 8302490. ISSN: 0755-4982.  
 CY France  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA French  
 FS Priority Journals  
 EM 200212

ED    Entered STN: 20021217  
 Last Updated on STN: 20021227  
 Entered Medline: 20021223

L11 ANSWER 91 OF 171       MEDLINE on STN

Full	Cited
Text	References

AN 2002705069       MEDLINE  
 DN PubMed ID: 12466318  
 TI Renal and cardiovascular protection in type 2 **diabetes** mellitus:  
 angiotensin II receptor blockers.  
 AU Deferrari Giacomo; Ravera Maura; Deferrari Luca; Vettoretti Simone; Ratto  
 Elena; Parodi Denise  
 CS Department of Internal Medicine, Section of Nephrology and Dialysis,  
 University of Genoa, Genoa, Italy.. [gildaplm@unige.it](mailto:gildaplm@unige.it)  
 SO Journal of the American Society of Nephrology : JASN, (2002 Nov) 13 Suppl  
 3 S224-9. Ref: 53  
 Journal code: 9013836. ISSN: 1046-6673.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200304  
 ED Entered STN: 20021217  
 Last Updated on STN: 20030417  
 Entered Medline: 20030415

L11 ANSWER 92 OF 171       MEDLINE on STN

Full	Cited
Text	References

AN 2002670490       MEDLINE  
 DN PubMed ID: 12430248  
 TI Evidence for the benefits of ACE inhibitors and AII antagonists in slowing  
 progressive renal failure in **diabetes**.  
 AU Suzuki Hiromichi  
 CS Department of Nephrology, Saitama Medical School.  
 SO Nippon rinsho. Japanese journal of clinical medicine, (2002 Oct) 60 Suppl  
 10 323-8. Ref: 12  
 Journal code: 0420546. ISSN: 0047-1852.  
 CY Japan  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA Japanese  
 FS Priority Journals  
 EM 200302  
 ED Entered STN: 20021115  
 Last Updated on STN: 20030221  
 Entered Medline: 20030220

L11 ANSWER 93 OF 171       MEDLINE on STN

Full	Cited
Text	References

AN 2002670486       MEDLINE  
 DN PubMed ID: 12430244  
 TI Evidence based treatment of **diabetic** nephropathy.  
 AU Sugimoto Toshiro  
 CS Third Department of Medicine, Shiga University of Medical Science.  
 SO Nippon rinsho. Japanese journal of clinical medicine, (2002 Oct) 60 Suppl  
 10 294-300. Ref: 24  
 Journal code: 0420546. ISSN: 0047-1852.  
 CY Japan  
 DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA Japanese  
 FS Priority Journals  
 EM 200302  
 ED Entered STN: 20021115  
 Last Updated on STN: 20030221  
 Entered Medline: 20030220

L11 ANSWER 94 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2002670481 MEDLINE  
 DN PubMed ID: 12430239  
 TI **Diabetic nephropathy.**  
 AU Haneda Masakazu  
 CS Third Department of Medicine, Shiga University of Medical Science.  
 SO Nippon rinsho. Japanese journal of clinical medicine, (2002 Oct) 60 Suppl 10 260-9. Ref: 23  
 Journal code: 0420546. ISSN: 0047-1852.  
 CY Japan  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA Japanese  
 FS Priority Journals  
 EM 200302  
 ED Entered STN: 20021115  
 Last Updated on STN: 20030221  
 Entered Medline: 20030220

L11 ANSWER 95 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2002658246 MEDLINE  
 DN PubMed ID: 12401753  
 TI Proteinuria as a predictor of total plasma homocysteine levels in type 2 **diabetic nephropathy.**  
 AU Friedman Alton N; Hunsicker Lawrence G; Selhub Jacob; Boston Andrew G  
 CS Vitamin Metabolism and Aging, Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts 02111, USA. (Collaborative Study Group).  
fried957@pac1.com  
 NC R01 HL 67695-02 (NHLBI)  
 SO Diabetes care, (2002 Nov) 25 (11) 2037-41.  
 Journal code: 7805975. ISSN: 0149-5992.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200304  
 ED Entered STN: 20021107  
 Last Updated on STN: 20030418  
 Entered Medline: 20030417

L11 ANSWER 96 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2002653107 IN-PROCESS  
 DN PubMed ID: 12410857  
 TI Angiotensin blockade in type 2 **diabetic** renal disease.  
 AU Ruilope Luis Miguel; Luno Jose  
 CS Unidad de Hipertension, Hospital 12 de Octubre, and Servicio de Nefrologia, Hospital General Universitario Gregorio Maranon, Madrid, Spain.  
 SO Kidney international. Supplement, (2002 Dec) (82) 61-3.

Journal code: 7508622. ISSN: 0098-6577.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals  
 ED Entered STN: 20021105  
 Last Updated on STN: 20021211

L11 ANSWER 97 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2002652897 MEDLINE  
 DN PubMed ID: 12411451  
 TI Angiotensin blockade prevents type 2 **diabetes** by formation of fat cells.  
 AU Sharma Arya M; Janke Jurgen; Gorzelnik Kerstin; Engeli Stefan; Luft Friedrich C  
 CS HELIOS Klinikum Berlin, Franz Volhard Clinic-Charite, Humboldt University of Berlin, and Max Delbruck Center for Molecular Medicine, Berlin, Germany.. [sharma@ccc.mcmaster.ca](mailto:sharma@ccc.mcmaster.ca)  
 SO Hypertension, (2002 Nov) 40 (5) 609-11.  
 Journal code: 7906255. ISSN: 1524-4563.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200211  
 ED Entered STN: 20021105  
 Last Updated on STN: 20021211  
 Entered Medline: 20021108

L11 ANSWER 98 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2002650227 MEDLINE  
 DN PubMed ID: 12409940  
 TI Antihypertensive treatment in patients with type-2 **diabetes** mellitus: what guidance from recent controlled randomized trials?.  
 AU Zanchetti Alberto; Ruilope Luis M  
 CS Centro di Fisiologia Clinica e Ipertensione, Universita di Milano, Ospedale Maggiore and Istituto Auxologico Italiano, Milano, Italy.. [zanchetti@mailserver.unimi.it](mailto:zanchetti@mailserver.unimi.it)  
 SO Journal of hypertension, (2002 Nov) 20 (11) 2099-110. Ref: 55  
 Journal code: 8306882. ISSN: 0263-6352.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW LITERATURE)  
 LA English  
 FS Priority Journals  
 EM 200305  
 ED Entered STN: 20021105  
 Last Updated on STN: 20030530  
 Entered Medline: 20030529

L11 ANSWER 99 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2002643663 MEDLINE  
 DN PubMed ID: 12402931  
 TI EC approves **irbesartan** for the treatment of **diabetic** renal disease.  
 AU Anonymous  
 SO Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, (2002 Jul-Aug) 13 (4) 216-7.  
 Journal code: 100964061. ISSN: 1015-9657.

CY South Africa  
 DT News Announcement  
 LA English  
 FS Priority Journals  
 EM 200212  
 ED Entered STN: 20021030  
 Last Updated on STN: 20021218  
 Entered Medline: 20021213

L11 ANSWER 100 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2002642476 MEDLINE  
 DN PubMed ID: 12401731  
 TI Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.  
 AU Sasso Ferdinando C; Carbonara Ornella; Persico Marcello; Iafusco Dario; Salvatore Teresa; D'Ambrosio Rosanna; Torella Roberto; Cozzolino Domenico  
 CS Internal Medicine Unit, Second University of Naples, Naples, Italy.  
 Pediatrics Unit, Second University of Naples, Naples, Italy..  
ferdinando.sasso@unima2.it  
 SO Diabetes care, (2002 Nov) 25 (11) 1909-13.  
 Journal code: 7805975. ISSN: 0149-5992.  
 CY United States  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LA English  
 FS Priority Journals  
 EM 200304  
 ED Entered STN: 20021029  
 Last Updated on STN: 20030418  
 Entered Medline: 20030417

L11 ANSWER 101 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2002639612 MEDLINE  
 DN PubMed ID: 12398574  
 TI Amlodipine versus Angiotensin-receptor blockers for nonhypertension indications.  
 AU Kalus James S; White C Michael  
 CS Hartford Hospital/University of Connecticut, Hartford, CT, USA.  
 SO Annals of pharmacotherapy, (2002 Nov) 36 (11) 1759-66. Ref: 47  
 Journal code: 9203131. ISSN: 1060-0280.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, ACADEMIC)  
 LA English  
 FS Priority Journals  
 EM 200302  
 ED Entered STN: 20021026  
 Last Updated on STN: 20030222  
 Entered Medline: 20030221

L11 ANSWER 102 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2002638906 MEDLINE  
 DN PubMed ID: 12397704  
 TI Large scale clinical trials in prevention of end-stage renal disease due to type 2 diabetes with angiotensin receptor antagonists.  
 AU Suzuki Hiromichi

CS Department of Nephrology, Saitama Medical School.  
 SO Nippon rinsho. Japanese journal of clinical medicine, (2002 Oct) 60 (10)  
 2040-4. Ref: 5  
 Journal code: 0420546. ISSN: 0047-1852.  
 CY Japan  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW LITERATURE)  
 LA Japanese  
 FS Priority Journals  
 EM 200212  
 ED Entered STN: 20021026  
 Last Updated on STN: 20021219  
 Entered Medline: 20021218

L11 ANSWER 103 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2002629891 MEDLINE  
 DN PubMed ID: 12387069  
 TI What is a good marker for better antihypertensive therapy in **diabetic**  
 patients when coexisting with hypertension.  
 AU Eguchi Kazuo; Kario Kazuomi; Shimada Kazuyuki  
 CS Department of Internal Medicine, Nishiarita Kyoritsu Hospital.  
 SO Nippon rinsho. Japanese journal of clinical medicine, (2002 Sep) 60 Suppl  
 9 679-84. Ref: 29  
 Journal code: 0420546. ISSN: 0047-1852.  
 CY Japan  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA Japanese  
 FS Priority Journals  
 EM 200212  
 ED Entered STN: 20021022  
 Last Updated on STN: 20021227  
 Entered Medline: 20021224

L11 ANSWER 104 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2002625743 MEDLINE  
 DN PubMed ID: 12383593  
 TI The role of angiotensin II receptor blockers in preventing the progression  
 of renal disease in patients with type 2 **diabetes**.  
 AU Lewis Edmund J  
 CS Department of Nephrology, Rush-Presbyterian-St. Luke's Medical Center,  
 Chicago, Illinois 60612, USA.  
 SO American journal of hypertension : journal of the American Society of  
 Hypertension, (2002 Oct) 15 (10 Pt 2) 123S-128S. Ref: 24  
 Journal code: 8803676. ISSN: 0895-7061.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW LITERATURE)  
 LA English  
 FS Priority Journals  
 EM 200303  
 ED Entered STN: 20021018  
 Last Updated on STN: 20030304  
 Entered Medline: 20030303

L11 ANSWER 105 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2002497805 MEDLINE  
 DN PubMed ID: 12358875  
 TI Type 2 **diabetes**, obesity, and the renal response to blocking the renin system with **irbesartan**.  
 AU Price D A; Lansang M C; Osei S Y; Fisher N D L; Laffel L M B; Hollenberg N K  
 CS Departments of Medicine and Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.. [DAPrice@Partners.org](mailto:DAPrice@Partners.org)  
 NC 1K23K0281601 (NCRR)  
 1P50ML 5300001  
 M01RR026376 (NIDDK)  
 P01AC00059916 (NHLBI)  
 R01 DK54668-01  
 T32 HL-07609  
 SO Diabetic medicine : a journal of the British Diabetic Association, (2002 Oct) 19 (10) 858-61.  
 Journal code: 8500858. ISSN: 0742-3071.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200301  
 ED Entered STN: 20021003  
 Last Updated on STN: 20030124  
 Entered Medline: 20030123

L11 ANSWER 106 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2002463816 MEDLINE  
 DN PubMed ID: 12222627  
 TI Evolving therapeutic strategies for retarding progression of **diabetic** nephropathy--an update for 2002.  
 AU Epstein M  
 CS Nephrology Section, VA Medical Center, Miami, FL 33125, USA.  
 SO Acta diabetologica, (2002 Jun) 39 Suppl 2 S41-5. Ref: 21  
 Journal code: 9200299. ISSN: 0940-5429.  
 CY Germany: Germany, Federal Republic of  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200303  
 ED Entered STN: 20020912  
 Last Updated on STN: 20030327  
 Entered Medline: 20030326

L11 ANSWER 107 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2002427796 MEDLINE  
 DN PubMed ID: 12184030  
 TI [**Irbesartan**--antihypertensive treatment in patients with heart failure and **diabetes mellitus**].  
**Irbesartan** w terapii nadciśnienia tetriczego u chorych z niewydolnością kراżenia i cukrzyca.  
 AU Zukowska-Szczechowska Ewa; Gosek Katarzyna; Grzeszczak Wladyslaw  
 CS Klinika Chorob Wewnętrznych i Diabetologii, Śląskiej Akademii Medycznej w Zabrzu.  
 SO Przeglad lekarski, (2002) 59 (3) 160-4. Ref: 52  
 Journal code: 19840720R. ISSN: 0033-2240.  
 CY Poland  
 DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)  
 (REVIEW, TUTORIAL)

LA Polish  
 FS Priority Journals  
 EM 200210  
 ED Entered STN: 20020820  
 Last Updated on STN: 20021031  
 Entered Medline: 20021030

L11 ANSWER 108 OF 171 MEDLINE on STN

Full  Citations  
 Text  References

AN 2002425841 MEDLINE  
 DN PubMed ID: 12182249  
 TI The role of angiotensin II antagonism in type 2 **diabetes** mellitus: a review of renoprotection studies.  
 AU Zanella Maria-Teresa; Ribeiro Artur B  
 CS Division of Nephrology, Hospital do Rim e Hipertensao, Federal University of Sao Paulo, Sao Paulo, Brazil.. [terezazanella@hrim.com.br](mailto:terezazanella@hrim.com.br)  
 SO Clinical therapeutics; (2002 Jul) 24 (7) 1019-34. Ref: 76  
 Journal code: 7706726. ISSN: 0149-2918.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200303  
 ED Entered STN: 20020817  
 Last Updated on STN: 20030311  
 Entered Medline: 20030310

L11 ANSWER 109 OF 171 MEDLINE on STN

Full  Citations  
 Text  References

AN 2002418229 MEDLINE  
 DN PubMed ID: 12172324  
 TI Renal expression of angiotensin receptors in long-term **diabetes** and the effects of angiotensin type 1 receptor blockade.  
 AU Bonnet Fabrice; Candido Riccardo; Carey Robert M; Casley David; Russo Leileata M; Osicka Tanya M; Cooper Mark E; Cao Zemin  
 CS Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg West, Victoria 3081, Australia.  
 SO Journal of hypertension, (2002 Aug) 20 (8) 1615-24.  
 Journal code: 8306882. ISSN: 0263-6352.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200302  
 ED Entered STN: 20020813  
 Last Updated on STN: 20030207  
 Entered Medline: 20030206

L11 ANSWER 110 OF 171 MEDLINE on STN

Full  Citations  
 Text  References

AN 2002386325 MEDLINE  
 DN PubMed ID: 12134723  
 TI [ACE inhibitor or AT1 antagonist. Is there a differential therapy?]. ACE-Hemmer oder AT1-Antagonist. Gibt es eine Differenzialtherapie?.  
 AU Unger Th; Rangoonwala B; Rosenthal J  
 CS Institut fur Pharmakologie und Toxikologie, Universitatsklinikum Charite der Humboldt Universitat, Berlin.. [thomas.unger@charite.de](mailto:thomas.unger@charite.de)  
 SO MMW Fortschritte der Medizin, (2002 Jun 13) 144 (24) 36-8.

CY Journal code: 100893959. ISSN: 1438-3276.  
 CY Germany: Germany, Federal Republic of  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA German  
 FS Priority Journals  
 EM 200210  
 ED Entered STN: 20020724  
 Last Updated on STN: 20021002  
 Entered Medline: 20021001

L11 ANSWER 111 OF 171 MEDLINE on STN

Full  Citing  References  
Text

AN 2002375011 MEDLINE  
 DN PubMed ID: 12121010  
 TI Recent landmark clinical trials: how do they modify the therapeutic paradigm?.  
 AU Epstein Murray  
 CS Department of Medicine, University of Miami School of Medicine, Florida 33125, USA.. [murraye@gate.net](mailto:murraye@gate.net)  
 SO American journal of hypertension : journal of the American Society of Hypertension, (2002 Jul) 15 (7 Pt 2) 82S-84S. Ref: 13  
 Journal code: 8803676. ISSN: 0895-7061.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW LITERATURE)  
 LA English  
 FS Priority Journals  
 EM 200301  
 ED Entered STN: 20020718  
 Last Updated on STN: 20030111  
 Entered Medline: 20030110

L11 ANSWER 112 OF 171 MEDLINE on STN

Full  Citing  References  
Text

AN 2002303473 MEDLINE  
 DN PubMed ID: 12045787  
 TI Angiotensin blockade in type 2 **diabetes**: what the new evidence tells us about renal and cardiac complications.  
 AU Studney Donald  
 CS University of British Columbia, Vancouver, Canada.. [studney@interchange.ubc.ca](mailto:studney@interchange.ubc.ca)  
 SO Canadian journal of cardiology, (2002 May) 18 Suppl A 3A-6A. Ref: 11  
 Journal code: 8510280. ISSN: 0828-282X.  
 CY Canada  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200206  
 ED Entered STN: 20020605  
 Last Updated on STN: 20020626  
 Entered Medline: 20020625

L11 ANSWER 113 OF 171 MEDLINE on STN

Full  Citing  References  
Text

AN 2002292224 MEDLINE  
 DN PubMed ID: 12032191  
 TI Dual blockade of the renin-angiotensin system in type 1 patients with **diabetic** nephropathy.  
 AU Jacobsen Peter; Andersen Steen; Rossing Kasper; Hansen Birgitte V; Parving

Hans-Henrik  
 CS Steno Diabetes Center, Gentofte, Denmark.. [pkjacobsen@dadlnet.dk](mailto:pkjacobsen@dadlnet.dk)  
 SO Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, (2002 Jun) 17 (6) 1019-24.  
 Journal code: 8706402. ISSN: 0931-0509.  
 CY England: United Kingdom  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LA English  
 FS Priority Journals  
 EM 200301  
 ED Entered STN: 20020529  
 Last Updated on STN: 20030111  
 Entered Medline: 20030110

L11 ANSWER 114 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2002274881 MEDLINE  
 DN PubMed ID: 12015188  
 TI Rationale and design of **diabetics** exposed to **telmisartan** and enalapril (DETAIL) study.  
 AU Rippin J; Bain S C; Barnett A H  
 CS Department of Medicine, University of Birmingham, Birmingham B9 5SS, UK.  
 (DETAIL study).  
 SO Journal of diabetes and its complications, (2002 May-Jun) 16 (3) 195-200.  
 Journal code: 9204583. ISSN: 1056-8727.  
 CY United States  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (MULTICENTER STUDY)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LA English  
 FS Priority Journals  
 EM 200210  
 ED Entered STN: 20020517  
 Last Updated on STN: 20021008  
 Entered Medline: 20021004

L11 ANSWER 115 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2002257703 MEDLINE  
 DN PubMed ID: 11996640  
 TI Class benefits of AT(1) antagonists in Type 2 **diabetes** with nephropathy.  
 AU Doggrell Sheila A  
 CS Department of Physiology and Pharmacology, School of Biomedical Sciences, University of Queensland, 4072 Australia.. [s\\_doggrell@yahoo.com](mailto:s_doggrell@yahoo.com)  
 SO Expert opinion on pharmacotherapy, (2002 May) 3 (5) 625-8.  
 Journal code: 100897346. ISSN: 1465-6566.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200209  
 ED Entered STN: 20020509  
 Last Updated on STN: 20020906  
 Entered Medline: 20020905

L11 ANSWER 116 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2002255828 MEDLINE

DN PubMed ID: 11996197  
 TI Current recommendations for the treatment of hypertension: are they still valid?.  
 AU Moser Marvin  
 CS Yale University School of Medicine, Scarsdale, New York 10583, USA..  
Moser@aol.com  
 SO Journal of hypertension, (2002 Feb) 20 Suppl 1 S3-10.  
 Journal code: 8306882. ISSN: 0263-6352.  
 CY England: United Kingdom  
 DT Editorial  
 LA English  
 FS Priority Journals  
 EM 200209  
 ED Entered STN: 20020509  
 Last Updated on STN: 20020912  
 Entered Medline: 20020911

L11 ANSWER 117 OF 171 MEDLINE on STN

Full     Citations  
 Text     References

AN 2002246981 MEDLINE  
 DN PubMed ID: 11985424  
 TI Irbesartan reduced progression of nephropathy caused by type 2 diabetes independent of the effect on blood pressure.  
 CM Comment on: N Engl J Med. 2001 Sep 20;345(12):851-60. PubMed ID: 11565517  
 AU Rabbat Christian G  
 CS McMaster University, Hamilton, Ontario, Canada.  
 SO ACP journal club, (2002 May-Jun) 136 (3) 82-4.  
 Journal code: 9104824. ISSN: 1056-8751.  
 CY United States  
 DT Commentary  
 Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS PUBMED-NOT-MEDLINE  
 EM 200205  
 ED Entered STN: 20020503  
 Last Updated on STN: 20020528  
 Entered Medline: 20020523

L11 ANSWER 118 OF 171 MEDLINE on STN

Full     Citations  
 Text     References

AN 2002246980 MEDLINE  
 DN PubMed ID: 11985423  
 TI Irbesartan was renoprotective in patients with type 2 diabetes, hypertension, and microalbuminuria.  
 CM Comment on: N Engl J Med. 2001 Sep 20;345(12):870-8. PubMed ID: 11565519  
 AU Rabbat Christian G  
 CS McMaster University, Hamilton, Ontario, Canada.  
 SO ACP journal club, (2002 May-Jun) 136 (3) 82-4.  
 Journal code: 9104824. ISSN: 1056-8751.  
 CY United States  
 DT Commentary  
 Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS PUBMED-NOT-MEDLINE  
 EM 200205  
 ED Entered STN: 20020503  
 Last Updated on STN: 20020528  
 Entered Medline: 20020523

L11 ANSWER 119 OF 171 MEDLINE on STN

Full     Citations  
 Text     References

AN 2002246309 MEDLINE

DN PubMed ID: 11986904  
 TI Angiotensin II receptor antagonists role in arterial hypertension.  
 AU Hernandez-Hernandez R; Sosa-Canache B; Velasco M; Armas-Hernandez M J;  
 Armas-Padilla M C; Cammarata R  
 CS Clinical Pharmacology Unit, Center of Biomedical Research, School of  
 Medicine, Universidad Centroccidental Lisandro Alvarado, Barquisimeto,  
 Venezuela.. [rhernan@cantv.net](mailto:rhernan@cantv.net)  
 SO Journal of human hypertension, (2002 Mar) 16 Suppl 1 S93-9. Ref: 59  
 Journal code: 8811625. ISSN: 0950-9240.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200207  
 ED Entered STN: 20020503  
 Last Updated on STN: 20020724  
 Entered Medline: 20020723

L11 ANSWER 120 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2002178953 MEDLINE  
 DN PubMed ID: 11910830  
 TI [Diabetic patient with hypertension takes A-I I blocker. Less likely dialysis].  
 Diabetiker mit Hochdruck nimmt A-II-Blocker. Seltener zur Dialyse.  
 AU Anonymous  
 SO MMW Fortschritte der Medizin, (2002 Feb 21) 144 (8) 52.  
 Journal code: 100893959. ISSN: 1438-3276.  
 CY Germany: Germany, Federal Republic of  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA German  
 FS Priority Journals  
 EM 200204  
 ED Entered STN: 20020326  
 Last Updated on STN: 20020420  
 Entered Medline: 20020419

L11 ANSWER 121 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2002170289 MEDLINE  
 DN PubMed ID: 11901904  
 TI [The best of 2001. Arterial hypertension].  
 L'essentiel de 2001 sur l'hypertension arterielle.  
 AU Laurent S  
 CS Service de pharmacologie, INSERM EMI 107, Hopital europeen  
 Georges-Pompidou, 20, rue Leblanc, 75015 Paris.  
 SO Archives des maladies du coeur et des vaisseaux, (2002 Jan) 95 Spec No 1  
 (5 Spec 1) 9-12. Ref: 12  
 Journal code: 0406011. ISSN: 0003-9683.  
 CY France  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA French  
 FS Priority Journals  
 EM 200210  
 ED Entered STN: 20020321  
 Last Updated on STN: 20021010  
 Entered Medline: 20021008

L11 ANSWER 122 OF 171 MEDLINE on STN

Full  
 Text     Clinical  
 References

AN 2002146932 MEDLINE  
DN PubMed ID: 11881102  
TI Effect of **telmisartan** on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and Type 2 **diabetes mellitus**.  
AU Asmar R  
CS L'Institut CardioVasculaire, Paris, 75016, France.. [ra@icv.org](mailto:ra@icv.org)  
SO Journal of the renin-angiotensin-aldosterone system : JRAAS, (2001 Sep) 2 Suppl 2 S8-11.  
Journal code: 100971636. ISSN: 1470-3203.  
CY England: United Kingdom  
DT (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
(MULTICENTER STUDY)  
(RANDOMIZED CONTROLLED TRIAL)  
LA English  
FS Priority Journals  
EM 200208  
ED Entered STN: 20020307  
Last Updated on STN: 20020813  
Entered Medline: 20020812

L11 ANSWER 123 OF 171 MEDLINE on STN

Full  
 Text     Clinical  
 References

AN 2002144432 MEDLINE  
DN PubMed ID: 11873779  
TI Angiotensin-receptor blockers, type 2 **diabetes**, and renoprotection.  
CM Comment on: N Engl J Med. 2001 Sep 20;345(12):851-60. PubMed ID: 11565517  
Comment on: N Engl J Med. 2001 Sep 20;345(12):861-9. PubMed ID: 11565518  
Comment on: N Engl J Med. 2001 Sep 20;345(12):870-8. PubMed ID: 11565519  
AU Ceriello Antonio; Motz Enrico  
SO New England journal of medicine, (2002 Feb 28) 346 (9) 705-7.  
Journal code: 0255562. ISSN: 1533-4406.  
CY United States  
DT Commentary  
Letter  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 200203  
ED Entered STN: 20020307  
Last Updated on STN: 20020307  
Entered Medline: 20020306

L11 ANSWER 124 OF 171 MEDLINE on STN

Full  
 Text     Clinical  
 References

AN 2002144431 MEDLINE  
DN PubMed ID: 11873778  
TI Angiotensin-receptor blockers, type 2 **diabetes**, and renoprotection.  
CM Comment on: N Engl J Med. 2001 Sep 20;345(12):851-60. PubMed ID: 11565517  
Comment on: N Engl J Med. 2001 Sep 20;345(12):861-9. PubMed ID: 11565518  
Comment on: N Engl J Med. 2001 Sep 20;345(12):870-8. PubMed ID: 11565519  
AU Walser Mackenzie  
SO New England journal of medicine, (2002 Feb 28) 346 (9) 705-7.  
Journal code: 0255562. ISSN: 1533-4406.  
CY United States  
DT Commentary  
Letter  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 200203  
ED Entered STN: 20020307

Last Updated on STN: 20020307  
 Entered Medline: 20020306

## L11 ANSWER 125 OF 171 MEDLINE on STN

Full  Cited  
 Text  References

AN 2002143947 MEDLINE  
 DN PubMed ID: 11881118  
 TI Renoprotection in Type 2 **diabetes**: blockade of the renin-angiotensin system with angiotensin II receptor blockers.  
 AU Swift P A; MacGregor G A  
 SO Journal of the renin-angiotensin-aldosterone system : JRAAS, (2001 Sep) 2 (3) 170-3. Ref: 27  
 Journal code: 100971636. ISSN: 1470-3203.  
 CY England: United Kingdom  
 DT Editorial  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200204  
 ED Entered STN: 20020307  
 Last Updated on STN: 20020424  
 Entered Medline: 20020423

## L11 ANSWER 126 OF 171 MEDLINE on STN

Full  Cited  
 Text  References

AN 2002143918 MEDLINE  
 DN PubMed ID: 11881063  
 TI Comparative antihypertensive and renoprotective effects of **telmisartan** and lisinopril after long-term treatment in hypertensive **diabetic** rats.  
 AU Wienen W; Richard S; Champeroux P; Audeval-Gerard C  
 CS Department of Pharma Research, Boehringer Ingelheim, Pharma KG, Biberach, Germany.. [wolfgang.wienen@bc.boehringer-ingelheim.com](mailto:wolfgang.wienen@bc.boehringer-ingelheim.com)  
 SO Journal of the renin-angiotensin-aldosterone system : JRAAS, (2001 Mar) 2 (1) 31-6.  
 Journal code: 100971636. ISSN: 1470-3203.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200204  
 ED Entered STN: 20020307  
 Last Updated on STN: 20020424  
 Entered Medline: 20020423

## L11 ANSWER 127 OF 171 MEDLINE on STN

Full  Cited  
 Text  References

AN 2002136221 MEDLINE  
 DN PubMed ID: 11871182  
 TI [Angiotensin 2 receptor blockaders: how do we explain the kidney-protective effect?].  
 Angiotensin-2-receptorblockare: hur forklarar vi den njurskyddande effekten?.  
 AU Arner Peter  
 CS Centrum for metabolism och endokrinologi, Huddinge Universitetssjukhus, Stockholm.. [peter.arner@medhs.ki.se](mailto:peter.arner@medhs.ki.se)  
 SO Lakartidningen, (2002 Jan 10) 99 (1-2) 80-2.  
 Journal code: 0027707. ISSN: 0023-7205.  
 CY Sweden  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA Swedish  
 FS Priority Journals

EM 200203  
 ED Entered STN: 20020302  
 Last Updated on STN: 20020403  
 Entered Medline: 20020327

## L11 ANSWER 128 OF 171 MEDLINE on STN

Full	Change
Text	References

AN 2002104848 MEDLINE  
 DN PubMed ID: 11835907  
 TI From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.  
 AU Yusuf Salim  
 CS Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.. [yusufs@mcmaster.ca](mailto:yusufs@mcmaster.ca)  
 SO American journal of cardiology, (2002 Jan 24) 89 (2A) 18A-25A; discussion 25A-26A.  
 Journal code: 0207277. ISSN: 0002-9149.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (META-ANALYSIS)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 200202  
 ED Entered STN: 20020212  
 Last Updated on STN: 20020223  
 Entered Medline: 20020222

## L11 ANSWER 129 OF 171 MEDLINE on STN

Full	Change
Text	References

AN 2002098783 MEDLINE  
 DN PubMed ID: 11828609  
 TI Preventing nephropathy in patients with type 2 **diabetes**.  
 AU Anonymous  
 SO Managed care interface, (2002 Jan) 15 (1) 72-5.  
 Journal code: 9715194. ISSN: 1096-5645.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Health  
 EM 200202  
 ED Entered STN: 20020207  
 Last Updated on STN: 20020228  
 Entered Medline: 20020227

## L11 ANSWER 130 OF 171 MEDLINE on STN

Full	Change
Text	References

AN 2002096064 MEDLINE  
 DN PubMed ID: 11825317  
 TI Angiotensin II receptor blockers for the treatment of hypertension.  
 AU See S  
 CS St. John's University College of Pharmacy, 8000 Utopia Parkway, NY 11439,  
 USA.. [sees@stjohns.edu](mailto:sees@stjohns.edu)  
 SO Expert opinion on pharmacotherapy, (2001 Nov) 2 (11) 1795-804. Ref: 52  
 Journal code: 100897346. ISSN: 1465-6566.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200209  
 ED Entered STN: 20020205

Last Updated on STN: 20020927  
 Entered Medline: 20020926

## L11 ANSWER 131 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2002092327 MEDLINE  
 DN PubMed ID: 11821641  
 TI Type 2 **diabetes**: RENAAL and IDNT--the emergence of new treatment options.  
 AU Sica Domenic A; Bakris George L  
 CS Section of Clinical Pharmacology and Hypertension, Division of Nephrology,  
 Medical College of Virginia of Virginia Commonwealth University, Richmond,  
 VA 23298-1060, USA.. [dsica@hsc.vcu.edu](mailto:dsica@hsc.vcu.edu)  
 SO Journal of clinical hypertension (Greenwich, Conn.), (2002 Jan-Feb) 4 (1)  
 52-7.  
 Journal code: 100888554. ISSN: 1524-6175.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200203  
 ED Entered STN: 20020201  
 Last Updated on STN: 20020319  
 Entered Medline: 20020318

## L11 ANSWER 132 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2002065095 MEDLINE  
 DN PubMed ID: 11791035  
 TI Additive antiproteinuric effect of combined ACE inhibition and angiotensin  
 II receptor blockade.  
 AU Ferrari Paolo; Marti Hans-Peter; Pfister Marc; Frey Felix J  
 CS Division of Nephrology and Hypertension, Inselspital, University of Berne,  
 Freiburgstrasse 10, 3010 Berne, Switzerland.. [paolet.ferrari@insel.ch](mailto:paolet.ferrari@insel.ch)  
 SO Journal of hypertension, (2002 Jan) 20 (1) 125-30.  
 Journal code: 8306882. ISSN: 0263-6352.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200204  
 ED Entered STN: 20020125  
 Last Updated on STN: 20020412  
 Entered Medline: 20020410

## L11 ANSWER 133 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2002051143 MEDLINE  
 DN PubMed ID: 11773985  
 TI The protective effect of blocking angiotensin in both type I and type II  
**diabetics** with nephropathy.  
 AU Beevers D G; Lip G Y  
 CS University Department of Medicine, City Hospital, Birmingham B18 7QH, UK..  
[g.y.h.lip@bham.ac.uk](mailto:g.y.h.lip@bham.ac.uk)  
 SO Journal of human hypertension, (2001 Dec) 15 (12) 837-9. Ref: 14  
 Journal code: 8811625. ISSN: 0950-9240.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200202

ED    Entered STN: 20020125  
 Last Updated on STN: 20020206  
 Entered Medline: 20020205

## L11 ANSWER 134 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 2002038112 MEDLINE  
 DN PubMed ID: 11765585  
 TI [Clinical study of the month. Nephroprotective role of angiotensin II receptor antagonists in type 2 **diabetes**: results of the IDNT and RENAAL trials].  
 Etude clinique du mois. Role nephroprotecteur des antagonistes du receiteur de l'angiotensine II (ARA) dans le **diabète** de type 2: resultats des etudes IDNT et RENAAL.  
 AU Weekers L; Krzesinski J M  
 CS Service de Nephrologie, CHU Sart-Tilman.  
 SO Revue medicale de Liege, (2001 Oct) 56 (10) 723-6.  
 Journal code: 0404317. ISSN: 0370-629X.  
 CY Belgium  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA French  
 FS Priority Journals  
 EM 200201  
 ED Entered STN: 20020124  
 Last Updated on STN: 20020125  
 Entered Medline: 20020104

## L11 ANSWER 135 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 2002030224 MEDLINE  
 DN PubMed ID: 11766619  
 TI Irbesartan slows the development of **diabetic** nephropathy by up to 70% in hypertensive **diabetic** patients.  
 AU Anonymous  
 SO Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, (2001 Aug-Sep) 12 (4) 242-3.  
 Journal code: 100964061. ISSN: 1015-9657.  
 CY South Africa  
 DT News Announcement  
 LA English  
 FS Priority Journals  
 EM 200201  
 ED Entered STN: 20020124  
 Last Updated on STN: 20020125  
 Entered Medline: 20020110

## L11 ANSWER 136 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 2002030222 MEDLINE  
 DN PubMed ID: 11766617  
 TI Irbesartan prevents the progression of kidney disease or death in patients with type 2 **diabetes** and high blood pressure.  
 AU Anonymous  
 SO Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, (2001 Aug-Sep) 12 (4) 240-1.  
 Journal code: 100964061. ISSN: 1015-9657.  
 CY South Africa  
 DT News Announcement  
 LA English

FS Priority Journals  
 EM 200201  
 ED Entered STN: 20020124  
 Last Updated on STN: 20020125  
 Entered Medline: 20020110

## L11 ANSWER 137 OF 171 MEDLINE on STN

Full  Cited  References  
 Text

AN 2002024119 MEDLINE  
 DN PubMed ID: 11465914  
 TI Hypertension and **diabetes**: the scope of the problem.  
 AU Parving H H  
 CS Steno Diabetes Center, Gentofte, Denmark.  
 SO Blood pressure. Supplement, (2001) 2 25-31. Ref: 39  
 Journal code: 9300787. ISSN: 0803-8023.  
 CY Norway  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200201  
 ED Entered STN: 20020121  
 Last Updated on STN: 20020125  
 Entered Medline: 20020110

## L11 ANSWER 138 OF 171 MEDLINE on STN

Full  Cited  References  
 Text

AN 2002008949 MEDLINE  
 DN PubMed ID: 11333010  
 TI The role of angiotensin II receptor antagonists in the management of **diabetes**.  
 AU Barnett A H  
 CS Birmingham Heartlands Hospital, Department of Medicine, UK.  
 SO Blood pressure. Supplement, (2001) 1 21-6. Ref: 41  
 Journal code: 9300787. ISSN: 0803-8023.  
 CY Norway  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200201  
 ED Entered STN: 20020121  
 Last Updated on STN: 20020125  
 Entered Medline: 20020108

## L11 ANSWER 139 OF 171 MEDLINE on STN

Full  Cited  References  
 Text

AN 2001648685 MEDLINE  
 DN PubMed ID: 11700829  
 TI Renal protection by angiotensin II receptor antagonists in patients with type 2 **diabetes**.  
 CM Comment in: Med J Aust. 2002 Mar 18;176(6):296-7; author reply 297. PubMed ID: 11999268  
 AU Jerums G; Cooper M E; Gilbert R E; Atkins R C  
 SO Medical journal of Australia, (2001 Oct 15) 175 (8) 397-9.  
 Journal code: 0400714. ISSN: 0025-729X.  
 CY Australia  
 DT Editorial  
 LA English  
 FS Priority Journals

EM 200112  
 ED Entered STN: 20011112  
 Last Updated on STN: 20020123  
 Entered Medline: 20011204

## L11 ANSWER 140 OF 171 MEDLINE on STN

Full  Citing  References  
 Text

AN 2001609714 MEDLINE  
 DN PubMed ID: 11684568  
 TI Drug companies should not have the final say in the design of clinical trials.  
 AU Kurtzman N A  
 SO American journal of kidney diseases : official journal of the National Kidney Foundation, (2001 Nov) 38 (5) 1113-4.  
 Journal code: 8110075. ISSN: 1523-6838.  
 CY United States  
 DT Editorial  
 LA English  
 FS Priority Journals  
 EM 200112  
 ED Entered STN: 20011102  
 Last Updated on STN: 20020123  
 Entered Medline: 20011204

## L11 ANSWER 141 OF 171 MEDLINE on STN

Full  Citing  References  
 Text

AN 2001562632 MEDLINE  
 DN PubMed ID: 11642211  
 TI [Current treatment of **diabetic** nephropathy in patients with type II **diabetes** mellitus. Most recent progress].  
 Tratamiento actual de la nefropatia **diabetica** en los pacientes con **diabetes** mellitus tipo 2. Ultimos avances.  
 AU de Alvaro F  
 CS Servicio de Nefrologia, Hospital La Paz, Madrid.  
 SO Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, (2001) 21 Suppl 3 76-82. Ref: 26  
 Journal code: 8301215. ISSN: 0211-6995.  
 CY Spain  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA Spanish  
 FS Priority Journals  
 EM 200206  
 ED Entered STN: 20011022  
 Last Updated on STN: 20020605  
 Entered Medline: 20020604

## L11 ANSWER 142 OF 171 MEDLINE on STN

Full  Citing  References  
 Text

AN 2001554478 MEDLINE  
 DN PubMed ID: 11601118  
 TI [Effect of **irbesartan** on the development of **diabetic** nephropathy in patients with type 2 **diabetes**].  
 Effekt af **irbesartan** pa udvikling af **diabetisk** nefropati hos patienter med type 2-**diabetes**.  
 AU Parving H H; Lehnert H; Brochner-Mortensen J; Gomis R; Andersen S; Arner P  
 CS Steno Diabetes Center, Gentofte.  
 SO Ugeskrift for Laeger, (2001 Oct 1) 163 (40) 5519-24.  
 Journal code: 0141730. ISSN: 0041-5782.  
 CY Denmark

DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LA Danish  
 FS Priority Journals  
 EM 200111  
 ED Entered STN: 20011017  
 Last Updated on STN: 20011105  
 Entered Medline: 20011101

L11 ANSWER 143 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2001530000 MEDLINE  
 DN PubMed ID: 11576953  
 TI A clinical trial in type 2 **diabetic** nephropathy.  
 AU Lewis E J; Hunsicker L G; Rodby R A  
 CS Section of Nephrology, Rush-Presbyterian-St. Luke's Medical Center,  
 Chicago, IL, USA. (Collaborative Study Group). [hfolmer@rush.edu](mailto:hfolmer@rush.edu)  
 SO American journal of kidney diseases : official journal of the National  
 Kidney Foundation, (2001 Oct) 38 (4 Suppl 1) S191-4.  
 Journal code: 8110075. ISSN: 1523-6838.  
 CY United States  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LA English  
 FS Priority Journals  
 EM 200112  
 ED Entered STN: 20011001  
 Last Updated on STN: 20020122  
 Entered Medline: 20011204

L11 ANSWER 144 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2001528110 MEDLINE  
 DN PubMed ID: 11574450  
 TI Angiotensin II receptor blockers and nephropathy trials.  
 CM Erratum in: Diabetes Care 2002 Jan;25(1):236  
 AU Bloomgarden Z T  
 SO Diabetes care, (2001 Oct) 24 (10) 1834-8.  
 Journal code: 7805975. ISSN: 0149-5992.  
 CY United States  
 DT Conference; Conference Article; (CONGRESSES)  
 LA English  
 FS Priority Journals  
 EM 200112  
 ED Entered STN: 20011001  
 Last Updated on STN: 20020321  
 Entered Medline: 20011205

L11 ANSWER 145 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2001518119 MEDLINE  
 DN PubMed ID: 11565519  
 TI The effect of **irbesartan** on the development of **diabetic** nephropathy in  
 patients with type 2 **diabetes**.  
 CM Comment in: ACP J Club. 2002 May-Jun;136(3):82-4. PubMed ID: 11985423  
 Comment in: N Engl J Med. 2001 Sep 20;345(12):910-2. PubMed ID: 11565525  
 Comment in: N Engl J Med. 2002 Feb 28;346(9):705-7. PubMed ID: 11870250  
 Comment in: N Engl J Med. 2002 Feb 28;346(9):705-7. PubMed ID: 11873779  
 Comment in: N Engl J Med. 2002 Feb 28;346(9):705-7. PubMed ID: 11873778  
 Comment in: Rev Cardiovasc Med. 2003 Spring;4(2):118-21. PubMed ID:

12776021  
AU Parving H H; Lehnert H; Brochner-Mortensen J; Gomis R; Andersen S; Arner P  
CS Steno Diabetes Center, Copenhagen, Denmark. (Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group).  
SO New England journal of medicine, (2001 Sep 20) 345 (12) 870-8.  
Journal code: 0255562. ISSN: 0028-4793.  
CY United States  
DT (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
(MULTICENTER STUDY)  
(RANDOMIZED CONTROLLED TRIAL)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 200109  
ED Entered STN: 20010924  
Last Updated on STN: 20020528  
Entered Medline: 20010927

L11 ANSWER 146 OF 171 MEDLINE on STN

Full  Abstract  
 Text  References

AN 2001518117 MEDLINE  
DN PubMed ID: 11565517  
TI Renoprotective effect of the angiotensin-receptor antagonist **irbesartan** in patients with nephropathy due to type 2 **diabetes**.  
CM Comment in: ACP J Club. 2002 May-Jun;136(3):82-4. PubMed ID: 11985424  
Comment in: N Engl J Med. 2001 Sep 20;345(12):910-2. PubMed ID: 11565525  
Comment in: N Engl J Med. 2002 Feb 28;346(9):705-7. PubMed ID: 11870250  
Comment in: N Engl J Med. 2002 Feb 28;346(9):705-7. PubMed ID: 11873779  
Comment in: N Engl J Med. 2002 Feb 28;346(9):705-7. PubMed ID: 11873778  
Comment in: Rev Cardiovasc Med. 2003 Spring;4(2):118-21. PubMed ID: 12776021  
AU Lewis E J; Hunsicker L G; Clarke W R; Berl T; Pohl M A; Lewis J B; Ritz E; Atkins R C; Rohde R; Raz I  
CS Department of Medicine, Rush-Presbyterian-St Luke's Medical Center, Chicago, IL 60612, USA. (Collaborative Study Group).  
SO New England journal of medicine, (2001 Sep 20) 345 (12) 851-60.  
Journal code: 0255562. ISSN: 0028-4793.  
CY United States  
DT (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
(MULTICENTER STUDY)  
(RANDOMIZED CONTROLLED TRIAL)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 200109  
ED Entered STN: 20010924  
Last Updated on STN: 20020528  
Entered Medline: 20010927

L11 ANSWER 147 OF 171 MEDLINE on STN

Full  Abstract  
 Text  References

AN 2001508169 MEDLINE  
DN PubMed ID: 11556191  
TI [Treatment of hypertension in patients with type 2 **diabetes**. Sartan also protects the kidneys]. Hochdrucktherapie bei Typ 2 **Diabetikern**. Sartan schützt auch die Nieren.  
AU Anonymous  
SO MMW Fortschritte der Medizin, (2001 Aug 9) 143 (31-32) 44.  
Journal code: 100893959. ISSN: 1438-3276.  
CY Germany: Germany, Federal Republic of  
DT News Announcement  
LA German  
FS Priority Journals

EM 200201  
 ED Entered STN: 20010917  
 Last Updated on STN: 20020125  
 Entered Medline: 20020103

L11 ANSWER 148 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2001462980 MEDLINE  
 DN PubMed ID: 11508272  
 TI **Irbesartan** normalises the deficiency in glomerular nephrin expression in a model of **diabetes** and hypertension.  
 AU Bonnet F; Cooper M E; Kawachi H; Allen T J; Boner G; Cao Z  
 CS Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg West, Victoria, Australia.  
 SO Diabetologia, (2001 Jul) 44 (7) 874-7.  
 Journal code: 0006777. ISSN: 0012-186X.  
 CY Germany: Germany, Federal Republic of  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200201  
 ED Entered STN: 20010820  
 Last Updated on STN: 20020124  
 Entered Medline: 20020102

L11 ANSWER 149 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2001451920 MEDLINE  
 DN PubMed ID: 11498657  
 TI New stuff about the **diabetic** kidney.  
 AU Townsend R R  
 CS Hypertension Program, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.  
 SO Journal of clinical hypertension (Greenwich, Conn.), (2001 Jul-Aug) 3 (4) 255.  
 Journal code: 100888554. ISSN: 1524-6175.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200110  
 ED Entered STN: 20010813  
 Last Updated on STN: 20011015  
 Entered Medline: 20011011

L11 ANSWER 150 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2001440495 MEDLINE  
 DN PubMed ID: 11461726  
 TI Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.  
 CM Comment in: Int J Cardiol. 2002 Dec;86(2-3):325-6. PubMed ID: 12419573  
 AU Coats A J  
 SO International journal of cardiology, (2001 Jul) 79 (2-3) 99-102. Ref: 16  
 Journal code: 8200291. ISSN: 0167-5273.  
 CY Ireland  
 DT Editorial  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200109

ED    Entered STN: 20010813  
       Last Updated on STN: 20030313  
       Entered Medline: 20010927

## L11 ANSWER 151 OF 171      MEDLINE on STN

Full	Citing
Text	References

AN 2001411210      MEDLINE  
 DN PubMed ID: 11460392  
 TI [Milestone studies provide evidence: sartans have a nephroprotective effect. Evidence is clear].  
 Meilenstein-Studien überzeugen: Sartane wirken nephroprotektiv. Evidenter geht's nicht.  
 AU Bold K O  
 SO MMW Fortschritte der Medizin, (2001 May 31) 143 (22) 12-3.  
 Journal code: 100893959. ISSN: 1438-3276.  
 CY Germany: Germany, Federal Republic of  
 DT News Announcement  
 LA German  
 FS Priority Journals  
 EM 200108  
 ED Entered STN: 20010903  
 Last Updated on STN: 20010903  
 Entered Medline: 20010830

## L11 ANSWER 152 OF 171      MEDLINE on STN

Full	Citing
Text	References

AN 2001406827      MEDLINE  
 DN PubMed ID: 11427096  
 TI Angiotensin II subtype 1 receptor blockers and renal function.  
 AU Toto R  
 CS Patient-Oriented Research in Nephrology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8856, USA..  
robert.toto@utsouthwestern.edu  
 SO Archives of internal medicine, (2001 Jun 25) 161 (12) 1492-9. Ref: 78  
 Journal code: 0372440. ISSN: 0003-9926.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 200107  
 ED Entered STN: 20010723  
 Last Updated on STN: 20010723  
 Entered Medline: 20010719

## L11 ANSWER 153 OF 171      MEDLINE on STN

Full	Citing
Text	References

AN 2001398377      MEDLINE  
 DN PubMed ID: 11450162  
 TI [Angiotensin receptor blockers--significance for the therapy of hypertension].  
 Angiotensin-Rezeptor-Blocker--Bedeutung für die Hochdrucktherapie.  
 AU Magometschnigg D  
 CS Institut für Hypertoniker, Kinderspitalgasse 10/15-17, A-1090 Wien..  
hypertonie@eunet.at  
 SO Wiener medizinische Wochenschrift (1946), (2001) 151 (7-8) 153-6. Ref: 55  
 Journal code: 8708475. ISSN: 0043-5341.  
 CY Austria  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)

LA German  
 FS Priority Journals  
 EM 200108  
 ED Entered STN: 20010827  
 Last Updated on STN: 20010827  
 Entered Medline: 20010823

## L11 ANSWER 154 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2001254660 MEDLINE  
 DN PubMed ID: 11352773  
 TI Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in **diabetic** spontaneously hypertensive rats.  
 AU Cao Z; Bonnet F; Davis B; Allen T J; Cooper M E  
 CS Department of Medicine, University of Melbourne, Austin & Repatriation Medical Centre, Heidelberg West 3081, Victoria, Australia..  
[cao@austin.unimelb.edu.au](mailto:cao@austin.unimelb.edu.au)  
 SO Clinical science (London, England : 1979), (2001 Jun) 100 (6) 591-9.  
 Journal code: 7905731. ISSN: 0143-5221.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200107  
 ED Entered STN: 20010709  
 Last Updated on STN: 20010709  
 Entered Medline: 20010705

## L11 ANSWER 155 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2001150705 MEDLINE  
 DN PubMed ID: 11104169  
 TI End-stage renal failure after **irbesartan** prescription in a **diabetic** patient with previously stable chronic renal insufficiency.  
 AU Descombes E; Fellay G  
 CS Department of Internal Medicine, Hopital Cantonal, Fribourg, Switzerland..  
[descombes@hopcantfr.ch](mailto:descombes@hopcantfr.ch)  
 SO Renal failure, (2000 Nov) 22 (6) 815-21.  
 Journal code: 8701128. ISSN: 0886-022X.  
 CY United States  
 DT (CASE REPORTS)  
 Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200103  
 ED Entered STN: 20010404  
 Last Updated on STN: 20010404  
 Entered Medline: 20010315

## L11 ANSWER 156 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2001136549 MEDLINE  
 DN PubMed ID: 11110232  
 TI A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of **irbesartan** in patients aged > or = 65 years with mild to moderate hypertension.  
 AU Lacourciere Y  
 CS Hypertension Unit, Centre Hospitalier Universitaire Laval, Quebec City, Quebec, Canada.  
 SO Clinical therapeutics, (2000 Oct) 22 (10) 1213-24.  
 Journal code: 7706726. ISSN: 0149-2918.

CY United States  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (MULTICENTER STUDY)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LA English  
 FS Priority Journals  
 EM 200103  
 ED Entered STN: 20010404  
 Last Updated on STN: 20010404  
 Entered Medline: 20010301

## L11 ANSWER 157 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 2001096652 MEDLINE  
 DN PubMed ID: 11129125  
 TI Lercanidipine: a review of its use in hypertension.  
 AU McClellan K J; Jarvis B  
 CS Adis International Limited, Auckland, New Zealand.. [demail@adis.co.nz](mailto:demail@adis.co.nz)  
 SO Drugs, (2000 Nov) 60 (5) 1123-40. Ref: 59  
 Journal code: 7600076. ISSN: 0012-6667.  
 CY New Zealand  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200102  
 ED Entered STN: 20010322  
 Last Updated on STN: 20010322  
 Entered Medline: 20010201

## L11 ANSWER 158 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 2000438371 MEDLINE  
 DN PubMed ID: 10854085  
 TI Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.  
 AU Israili Z H  
 CS Emory University School of Medicine, Atlanta, GA 30303, USA.  
 SO Journal of human hypertension, (2000 Apr) 14 Suppl 1 S73-86. Ref: 174  
 Journal code: 8811625. ISSN: 0950-9240.  
 CY ENGLAND: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, ACADEMIC)  
 LA English  
 FS Priority Journals  
 EM 200009  
 ED Entered STN: 20000928  
 Last Updated on STN: 20000928  
 Entered Medline: 20000915

## L11 ANSWER 159 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 2000438370 MEDLINE  
 DN PubMed ID: 10854084  
 TI Angiotensin II receptor antagonists in arterial hypertension.  
 AU Hernandez-Hernandez R; Velasco M; Armas-Hernandez M J; Armas-Padilla M C  
 CS Clinical Pharmacology Unit, Center of Biomedical Research, School of Medicine, Universidad Centroccidental Lisandro Alvarado, Barquisimeto, Venezuela.

SO Journal of human hypertension, (2000 Apr) 14 Suppl 1 S69-72. Ref: 34  
 Journal code: 8811625. ISSN: 0950-9240.  
 CY ENGLAND: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200009  
 ED Entered STN: 20000928  
 Last Updated on STN: 20000928  
 Entered Medline: 20000915

L11 ANSWER 160 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2000193846 MEDLINE  
 DN PubMed ID: 10727543  
 TI The **Irbesartan** type II **diabetic** nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.  
 AU Rodby R A; Rohde R D; Clarke W R; Hunsicker L G; Anzalone D A; Atkins R C; Ritz E; Lewis E J  
 CS The Section of Nephrology, Department of Medicine, Rush Medical College, Chicago, IL, USA.  
 SO Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, (2000 Apr) 15 (4) 487-97.  
 Journal code: 8706402. ISSN: 0931-0509.  
 CY ENGLAND: United Kingdom  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (MULTICENTER STUDY)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LA English  
 FS Priority Journals  
 EM 200005  
 ED Entered STN: 20000525  
 Last Updated on STN: 20000525  
 Entered Medline: 20000517

L11 ANSWER 161 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2000190664 MEDLINE  
 DN PubMed ID: 10726465  
 TI [Organ protection in hypertensive type 2 **diabetic** patients. Double chance with AT1 blockers].  
 Organprotektion bei hypertensiven Typ-2-**Diabetikern**. Zweifache Chance mit AT1-Blockern.  
 AU Anonymous  
 SO MMW Fortschritte der Medizin, (2000 Jan 20) 142 (3) 58-9.  
 Journal code: 100893959. ISSN: 1438-3276.  
 CY GERMANY: Germany, Federal Republic of  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA German  
 FS Priority Journals  
 EM 200004  
 ED Entered STN: 20000421  
 Last Updated on STN: 20000421  
 Entered Medline: 20000411

L11 ANSWER 162 OF 171 MEDLINE on STN

Full	Citing
Text	References

AN 2000094526 MEDLINE

DN PubMed ID: 10630830  
 TI Candesartan cilexetil: an angiotensin II receptor blocker.  
 AU Stoukides C A; McVoy H J; Kaul A F  
 CS Medical Outcomes Management, Inc., Foxborough, MA 02035, USA.  
 SO Annals of pharmacotherapy, (1999 Dec) 33 (12) 1287-98. Ref: 72  
 Journal code: 9203131. ISSN: 1060-0280.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 200002  
 ED Entered STN: 20000209  
 Last Updated on STN: 20030313  
 Entered Medline: 20000203

L11 ANSWER 163 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2000081217 MEDLINE  
 DN PubMed ID: 10614150  
 TI [Antihypertensive advantages of angiotensin II AT1 receptor antagonism].  
 Ventajas antihipertensivas del antagonismo de los receptores AT1 de la  
 angiotensina II.  
 AU Coca A; Giner V  
 CS Departamento de Medicina, Instituto de Investigaciones Biomedicas August  
 Pi Sunyer (IDIBAPS), Hospital Clinico, Universidad de Barcelona.  
 SO Revista espanola de cardiologia, (1999) 52 Suppl 3 53-8. Ref: 47  
 Journal code: 0404277. ISSN: 0300-8932.  
 CY Spain  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA Spanish  
 FS Priority Journals  
 EM 200001  
 ED Entered STN: 20000131  
 Last Updated on STN: 20000131  
 Entered Medline: 20000114

L11 ANSWER 164 OF 171 MEDLINE on STN

Full  Citing  
 Text  References

AN 2000007311 MEDLINE  
 DN PubMed ID: 10541298  
 TI The paradox of the low-renin state in **diabetic** nephropathy.  
 AU Price D A; Porter L E; Gordon M; Fisher N D; De'Oliveira J M; Laffel L M;  
 Passan D R; Williams G H; Hollenberg N K  
 CS Department of Medicine, Harvard Medical School and Brigham and Women's  
 Hospital, Boston, Massachusetts 02115, USA.. [daprince@bics.bwh.harvard.edu](mailto:daprince@bics.bwh.harvard.edu)  
 NC M01 RR-026376 (NCRR)  
 P01AC00059916  
 T32 HL-07609 (NHLBI)  
 +  
 SO Journal of the American Society of Nephrology : JASN, (1999 Nov) 10 (11)  
 2382-91.  
 Journal code: 9013836. ISSN: 1046-6673.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals; Space Life Sciences  
 EM 199911  
 ED Entered STN: 20000111  
 Last Updated on STN: 20000111

Entered Medline: 19991118

L11 ANSWER 165 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 1999372258 MEDLINE  
 DN PubMed ID: 10443311  
 TI [Are the antagonists of angiotensin II AT1 receptors protectors of the kidney?].  
 Les antagonistes des récepteurs AT1 de l'angiotensine II sont-ils nephroprotecteurs?.  
 AU Deray G  
 CS Service de néphrologie, Groupe hospitalier La Pitié-La Salpêtrière, Paris.  
 SO Archives des maladies du cœur et des vaisseaux, (1999 Jul) 92 (7) 903-7.  
 Ref: 26  
 Journal code: 0406011. ISSN: 0003-9683.  
 CY France  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA French  
 FS Priority Journals  
 EM 199909  
 ED Entered STN: 19990925  
 Last Updated on STN: 19990925  
 Entered Medline: 19990909

L11 ANSWER 166 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 1999216066 MEDLINE  
 DN PubMed ID: 10201883  
 TI Comparative antihypertensive effects of angiotensin II receptor antagonists.  
 AU Burnier M; Brunner H R  
 CS Division of Hypertension and Vascular Medicine, Lausanne, Switzerland..  
Michel.Burnier@chuv.hospvd.ch  
 SO Journal of the American Society of Nephrology : JASN, (1999 Apr) 10 Suppl 12 S278-82. Ref: 40  
 Journal code: 9013836. ISSN: 1046-6673.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 199909  
 ED Entered STN: 19990921  
 Last Updated on STN: 19990921  
 Entered Medline: 19990909

L11 ANSWER 167 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 1999070669 MEDLINE  
 DN PubMed ID: 9855027  
 TI Optimizing antihypertensive therapy in patients with **diabetic** nephropathy.  
 AU Ritz E; Rychlik I; Miltenberger-Miltenyi G  
 CS Department of Internal Medicine, Ruperto Carola University, Heidelberg, Germany.  
 SO Journal of hypertension. Supplement : official journal of the International Society of Hypertension, (1998 Sep) 16 (7) S17-22. Ref: 54  
 Journal code: 8501422. ISSN: 0952-1178.  
 CY ENGLAND: United Kingdom

DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (RANDOMIZED CONTROLLED TRIAL)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 199902  
 ED Entered STN: 19990311  
 Last Updated on STN: 19990311  
 Entered Medline: 19990222

L11 ANSWER 168 OF 171 MEDLINE on STN

Full  Clincial  
 Text  References

AN 1998193697 MEDLINE  
 DN PubMed ID: 9532518  
 TI Clinical overview of **irbesartan**: expanding the therapeutic window in hypertension.  
 AU Man in't Veld A J  
 CS Department of Internal Medicine, Academisch Ziekenhuis Dijkzigt, Rotterdam, The Netherlands.  
 SO Journal of hypertension. Supplement : official journal of the International Society of Hypertension, (1997 Dec) 15 (7) S27-33.  
 Journal code: 8501422. ISSN: 0952-1178.  
 CY ENGLAND: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (META-ANALYSIS)  
 LA English  
 FS Priority Journals  
 EM 199805  
 ED Entered STN: 19980609  
 Last Updated on STN: 19980609  
 Entered Medline: 19980528

L11 ANSWER 169 OF 171 MEDLINE on STN

Full  Clincial  
 Text  References

AN 1998193694 MEDLINE  
 DN PubMed ID: 9532515  
 TI Non-insulin-dependent **diabetes mellitus**, nephropathy, and the renin system.  
 AU Hollenberg N K  
 CS Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.  
 SO Journal of hypertension. Supplement : official journal of the International Society of Hypertension, (1997 Dec) 15 (7) S7-13. Ref: 52  
 Journal code: 8501422. ISSN: 0952-1178.  
 CY ENGLAND: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 199805  
 ED Entered STN: 19980609  
 Last Updated on STN: 19980609  
 Entered Medline: 19980528

L11 ANSWER 170 OF 171 MEDLINE on STN

Full  Clincial  
 Text  References

AN 1998099615 MEDLINE  
 DN PubMed ID: 9438777  
 TI Renoprotection and renin-angiotensin system blockade in **diabetes mellitus**.

AU Ruilope L M  
 CS Universidad Complutense, Chief Hypertension Unit, Hospital 12 de Octubre,  
     Madrid, Spain.  
 SO American journal of hypertension : journal of the American Society of  
     Hypertension, (1997 Dec) 10 (12 Pt 2) 325S-331S. Ref: 68  
     Journal code: 8803676. ISSN: 0895-7061.  
 CY United States  
 DT (CLINICAL TRIAL)  
     (CONTROLLED CLINICAL TRIAL)  
     Journal; Article; (JOURNAL ARTICLE)  
     General Review; (REVIEW)  
     (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 199802  
 ED Entered STN: 19980224  
     Last Updated on STN: 20000303  
     Entered Medline: 19980212

L11 ANSWER 171 OF 171 MEDLINE on STN

Full  Citation  
 Text  References

AN 1998071355 MEDLINE  
 DN PubMed ID: 9407464  
 TI **Irbesartan** lowers blood pressure and ameliorates renal injury in  
     experimental non-insulin-dependent **diabetes mellitus**.  
 AU O'Donnell M P; Crary G S; Oda H; Kasiske B L; Powell J R; Keane W F  
 CS Department of Medicine, Hennepin County Medical Center, Minneapolis, USA.  
 SO Kidney international. Supplement, (1997 Dec) 63 S218-20.  
     Journal code: 7508622. ISSN: 0098-6577.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199802  
 ED Entered STN: 19980217  
     Last Updated on STN: 19980217  
     Entered Medline: 19980205

=> d an ti au so kwic 148

L11 ANSWER 148 OF 171 MEDLINE on STN

Full  Citation  
 Text  References

AN 2001462980 MEDLINE  
 TI **Irbesartan** normalises the deficiency in glomerular nephrin expression in  
     a model of **diabetes** and hypertension.  
 AU Bonnet F; Cooper M E; Kawachi H; Allen T J; Boner G; Cao Z  
 SO Diabetologia, (2001 Jul) 44 (7) 874-7.  
     Journal code: 0006777. ISSN: 0012-186X.  
 TI **Irbesartan** normalises the deficiency in glomerular nephrin expression in  
     a model of **diabetes** and hypertension.  
 AB . . . key role in the function of the glomerular filtration barrier and  
     the development of proteinuria but its status in long-term **diabetes** is  
     still not understood. We studied the expression of nephrin in a  
     hypertensive model of **diabetic** nephropathy and investigated the  
     potential influence of angiotensin II blockade on nephrin gene and protein  
     expression. METHODS: Streptozotocin-**diabetic** spontaneously hypertensive  
     rats were given either no treatment or the angiotensin II antagonist,  
     **irbesartan**, at a dose of 15 mg/kg per day by gavage for 32 weeks.  
     Non-**diabetic** spontaneously hypertensive rats were used as a control  
     group. Real time RT-PCR and immunohistochemistry were used to assess and  
     quantify gene and protein expression of nephrin. RESULTS: **Diabetic**

spontaneously hypertensive rats developed albuminuria and had a reduction in both gene and protein expression of nephrin when compared with control rats. **Irbesartan** treatment prevented the development of albuminuria and completely abrogated the down regulation of nephrin in **diabetic** rats.

**CONCLUSION/INTERPRETATION:** Long-term **diabetes** in spontaneously hypertensive rats is associated with a reduction in both gene and protein expression of nephrin within the kidney.. . .

CT Check Tags: Male; Support, Non-U.S. Gov't

Albuminuria: PC, prevention & control

Analysis of Variance

Animals

\*Biphenyl Compounds: PD, pharmacology

**Diabetes Mellitus, Experimental:** DT, drug therapy

\***Diabetes Mellitus, Experimental:** PP, physiopathology

Disease Models, Animal

Gene Expression Regulation: DE, drug effects

\*Hypertension: DT, drug therapy

Oligonucleotide Probes

\*Proteins: . . .

RN 138402-11-6 (irbesartan)

=> d an ti au so kwic 147

L11 ANSWER 147 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 2001508169 MEDLINE

TI [Treatment of hypertension in patients with type 2 **diabetes**. Sartan also protects the kidneys].

Hochdrucktherapie bei Typ 2 **Diabetikern**. Sartan schützt auch die Nieren.

AU Anonymous

SO MMW Fortschritte der Medizin, (2001 Aug 9) 143 (31-32) 44.  
Journal code: 100893959. ISSN: 1438-3276.

TI [Treatment of hypertension in patients with type 2 **diabetes**. Sartan also protects the kidneys].

Hochdrucktherapie bei Typ 2 **Diabetikern**. Sartan schützt auch die Nieren.

CT . . .

AE, adverse effects

\*Antihypertensive Agents: TU, therapeutic use

Biphenyl Compounds: AE, adverse effects

\*Biphenyl Compounds: TU, therapeutic use

Clinical Trials

\***Diabetes Mellitus, Type II:** DT, drug therapy

\***Diabetic Nephropathies:** PC, prevention & control

\*Hypertension: DT, drug therapy

\*Receptors, Angiotensin: AI, antagonists & inhibitors

Tetrazoles: AE, adverse effects

\*Tetrazoles: . . .

RN 138402-11-6 (irbesartan)

=> d an ti au so kwic 139

L11 ANSWER 139 OF 171 MEDLINE on STN

Full	Cited
Text	References

AN 2001648685 MEDLINE

TI Renal protection by angiotensin II receptor antagonists in patients with type 2 **diabetes**.

AU Jerums G; Cooper M E; Gilbert R E; Atkins R C

SO Medical journal of Australia, (2001 Oct 15) 175 (8) 397-9.  
Journal code: 0400714. ISSN: 0025-729X.

TI Renal protection by angiotensin II receptor antagonists in patients with

type 2 **diabetes**.  
 CT Check Tags: Female; Male  
   \*Angiotensin II  
   \*Biphenyl Compounds: AD, administration & dosage  
     Clinical Trials  
     **Diabetes Mellitus, Type 2: CO, complications**  
     **Diabetic Nephropathies: ET, etiology**  
     **\*Diabetic Nephropathies: PC, prevention & control**  
       Humans  
       Hypertension, Renal: ET, etiology  
     \*Hypertension, Renal: PC, prevention & control  
       Kidney: DE, drug effects

RN 11128-99-7 (Angiotensin II); 114798-26-4 (Losartan); **138402-11-6**  
 (**irbesartan**)

=> d an ti au so kwic 133

L11 ANSWER 133 OF 171        MEDLINE on STN

Full     Citations  
 Text     References

AN 2002051143        MEDLINE  
 TI The protective effect of blocking angiotensin in both type I and type II  
   **diabetics** with nephropathy.  
 AU Beevers D G; Lip G Y  
 SO Journal of human hypertension, (2001 Dec) 15 (12) 837-9. Ref: 14  
   Journal code: 8811625. ISSN: 0950-9240.  
 TI The protective effect of blocking angiotensin in both type I and type II  
   **diabetics** with nephropathy.  
 CT . . .  
 BI, biosynthesis  
   \*Angiotensin II: DE, drug effects  
   \*Angiotensin-Converting Enzyme Inhibitors: AD, administration & dosage  
     Biphenyl Compounds: AD, administration & dosage  
     **Diabetes Mellitus, Type I: CO, complications**  
     **Diabetes Mellitus, Type II: CO, complications**  
     **Diabetic Nephropathies: DT, drug therapy**  
     **\*Diabetic Nephropathies: PC, prevention & control**  
       Losartan: AD, administration & dosage  
       Middle Aged  
       Primary Prevention: MT, methods  
       Prognosis  
       Randomized Controlled Trials

RN 11128-99-7 (Angiotensin II); 114798-26-4 (Losartan); **138402-11-6**  
 (**irbesartan**); 9041-90-1 (Angiotensin I)

=> d an ti au so kwic 129

L11 ANSWER 129 OF 171        MEDLINE on STN

Full     Citations  
 Text     References

AN 2002098783        MEDLINE  
 TI Preventing nephropathy in patients with type 2 **diabetes**.  
 AU Anonymous  
 SO Managed care interface, (2002 Jan) 15 (1) 72-5.  
   Journal code: 9715194. ISSN: 1096-5645.  
 TI Preventing nephropathy in patients with type 2 **diabetes**.  
 CT Check Tags: Human  
   \*Antihypertensive Agents: AD, administration & dosage  
     Biphenyl Compounds: AD, administration & dosage

\***Diabetes Mellitus, Type II: CO, complications**  
**Diabetic Nephropathies: CO, complications**  
**\*Diabetic Nephropathies: PC, prevention & control**  
**\*Disease Management**  
**Hypertension: CO, complications**  
**\*Hypertension: DT, drug therapy**  
**Kidney Failure, Chronic: CO, complications**  
**Kidney.**

RN 114798-26-4 (Losartan); 138402-11-6 (irbesartan)

=> d an ti au so kwic 122

L11 ANSWER 122 OF 171 MEDLINE on STN

Full  Citations  
 Text  References

AN 2002146932 MEDLINE  
TI Effect of **telmisartan** on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and Type 2 **diabetes mellitus**.  
AU Asmar R  
SO Journal of the renin-angiotensin-aldosterone system : JRAAS, (2001 Sep) 2 Suppl 2 S8-11.  
Journal code: 100971636. ISSN: 1470-3203.  
TI Effect of **telmisartan** on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and Type 2 **diabetes mellitus**.  
AB . . . wall stiffness is an important independent risk factor for cardiovascular disease in hypertensive patients, which is further exacerbated by co-existent **diabetes mellitus**. Increased arterial stiffness is directly associated with an increase in pulse wave velocity (PWV) and indirectly with increased central . . . peripheral blood pressure. Following a two-week placebo run-in period, 27 patients with mild to moderate essential hypertension and Type 2 **diabetes mellitus**, were randomised to once daily treatment with either **telmisartan** 40 mg or placebo for three weeks, and after a two-week washout period, crossed-over to the alternative treatment for a . . . were measured using the SphygmoCor system, at the start and end of each treatment period. Compared with placebo, treatment with **telmisartan** significantly reduced carotid/femoral PWV (mean adjusted treatment difference -0.95 m/s, 95% confidence intervals: -1.67, -0.23 m/s, p=0.013), as well as peripheral and central diastolic, systolic and pulse pressure. In conclusion, the results of the this study show that **telmisartan** is effective in reducing arterial stiffness in hypertensive patients with Type 2 **diabetes mellitus**, and may potentially have beneficial effects on cardiovascular outcomes, beyond blood-pressure lowering effects in the patient group.

CT . . .  
Aged

\*Angiotensin-Converting Enzyme Inhibitors: TU, therapeutic use  
\*Benzimidazoles: TU, therapeutic use  
\*Benzoates: TU, therapeutic use  
Blood Pressure: DE, drug effects  
\*b**Diabetes Mellitus, Type II: CO, complications**  
Double-Blind Method  
\*Hypertension: DT, drug therapy  
Middle Aged  
Prospective Studies  
Pulsatile Flow: DE, drug effects

RN 144701-48-4 (telmisartan)

=>

